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ABSTRACT
Pas teurella multocida type A organisms of bovine origin obtained
from the pleural fluid of experimentally infected lambs were found
to express two unique outer membrane proteins of molecular masses
of 84 and 87 kDa. These proteins were also expre^ed in bacteria
grown in vitro under iron restriction in nutrient broth (NB)
containing 2,2'-dipyridyl, but not in bacteria grown in NB. Mice
were immunized with heat killed organisms which had been grown in
NB, NB containing 2,2'-dipyridyl, horse serum and in vivo, and good
protection was demonstrated. There was a suggestion that in vitro
grown P. multocida expressing these iron regulated proteins (IRP)
induced a slightly higher level of protection against challenge, but
this was not significant on statistical analysis. A greater
antibody response was observed in mice immunized with bacteria
expressing IRP compared to the other growth conditions as
determined by ELISA. However, no antibody response against the 84
and 87 kDa proteins could be demonstrated in Western blots.
Mice vaccinated with NB grown heat killed P. multocida induced
100% protection against a homologous challenge of 10 ^D,-q.
Vaccination of mice induced antibodies responsible for
complement-mediated bactericidal activity of serum and higher ELISA
titres to whole cells, compared to the unvaccinated controls. This
suggested that the protection was clearly associated with the
bactericidal antibodies. The correlation of bactericidal capacity
with whole-cell ELISA titres indicated that cell surface antigens
were involved in stimulating bactericidal antibodies.
Monoclonal antibodies (mAb) against P. multocida type A were
produced after vaccination of Balb/c mice with heat killed
organisms of NB containing 2,2'-dipyridyl grown cells. An IgM mAb
against the capsule agglutinated a capsular extract antigen-coated
sheep red blood cells but failed to protect mice. In contrast, an
anti-lipopolysaccharide (LPS) mAb of su^ class demonstrated
complement-mediated bactericidal capacity, protected mice passively
against a challenge of 10 ^50' ^ut was not haemagglutinating.
This mAb reacted with only 58% of P. multocida isolates in ELISA
and was shown by an ELISA inhibition test with fractions of LPS to
be specific for lipid A of the LPS molecule. The bactericidal
capacity of the lipid A reactive mAb against P. multocida isolates
correlated with the ELISA titres. A clear association between the
whole-cell ELISA titres, bactericidal capacity and Western blotting
of LPS of different isolates was established.
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History of the Disease
Pasteurellosis of cattle was first observed by Bollinger in
1878, while in 1880 the causative organism of fowl cholera was
isolated by Pasteur. Kitt in 1885 named the organism Bacterium
bipolare multocidum (Breed et al 1957) . Having observed the close
relationship of the organisms which cause bovine pasteurellosis,
fowl cholera and rabbit septicaemia, Huppe in 1886 proposed the
name Bacillus septicaemia for these bacteria (Buchanan and Murray
1916) . Kruse in 1886 introduced the name Bacillus bovisepticum
(Bain et al 1982). Lignierisi in 1901, introduced the generic name
of Pasteurella for the whole group of organisms which cause
pasteurellosis in animals in honour of Pasteur as suggested by
Trevisan in 1887 (Bain et al 1982) . Although Wilson and Miles
(1975) preferred P. septica, the name Pasteurella multocida
suggested by Rosenbusch and Merchant (1939) is now established.
P. multocida has been isolated from a wide variety of mammals
and birds. It is the cause of haemorrhagic septicaemia of cattle
and buffaloes in Southern Europe, North, Central and East Africa,
the Near East, and Southern and Southeast Asia (Bain et al 1982).
It is also associated with pneumonia of cattle, sheep and pigs;
fowl cholera and certain forms of mastitis in cattle and sheep
(Hussaini 1975). In pneumonic lungs of lambs, however, P.
haemolytica is more commonly isolated than P. multocida (Hamdy et
al 1959). The importance of P. multocida in the aetiology of
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pasteurellosis in rabbits reared for both commercial and laboratory
purposes is well recognized (Lu et al 1978, Percy et al 1984;
Manning 1984). The most common human infections associated with
Pasteurella species are those involving the respiratory tract and
those resulting from dog and cat bites (Meyer 1958; Carter 1967).
In 1977, Johnson and Rumans reported an unusual case of acute
epiglottitis in a man and it has also been reported to be a
commensal resident of the upper respiratory flora of healthy man
(Johnson and Rumans 1977) and animals (Gilmour 1978) .
Morphological, cultural and Biochemical Characteristics
Morphological Characteristics
P. multocida is a Gram-negative, non-motile, rod or
coccobacillus, which shows a characteristic bipolar staining with
Leishman and methylene blue stains. It is aerobic and
non-spore-forming, producing fine translucent colonies about one
millimeter in diameter with a characteristic musty odour on
nutrient agar (Carter 1979). These colonies are non-haemolytic,
and do not grow on MacConkey agar (Breed et al 1957) .
Cultural Characteristics / Colonial Variation
The existence of a large variety of terms to describe similar
colonial variations associated with P. multocida led Carter (1957)
to recommend that the scheme devised by Braun for the colonial
variations displayed by other bacteria be adopted for P. multocida.
Three principle variants were designated and they were mucoid,
smooth, and rough. The smooth variants were further differentiated
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on the presence or absence of iridescence in oblique light, as
smooth iridescent or smooth non-iridescent.
While prevailing types of P. multocida isolated from rabbits
were mucoid (Webster and Burn 1926) smooth, smooth iridescent and
smooth non- iridescent colonial variants have been isolated from
fowl cholera (Hughes 1930). The relationship of colonial variation
to virulence varies with the species of laboratory animal used.
Cultures initiated from mucoid and smooth variants were highly
virulent for mice whereas mucoid cultures that tend to autolyse
were weakly or moderately virulent (Carter and Bigland 1953) . As
iridescence was lost, mouse virulence may (Yaw et al 1956) or may
not (Carter 1957) drop. Low virulence in mice was observed with
rough variants of P. multocida (Anderson et al 1929). Study of
colonial dissociation revealed that the mucoid variant was derived
from the smooth form (Elberg and Cheng-Lee Ho 1950 ; Carter and
Bigland 1953), with the sequence of dissociation being smooth -->
mucoid > rough (Carter 1957) . A similar sequence to this has
been observed in vitro in a fowl cholera isolate (Heddleston et al
1964). Animal passage resulted in the replacement of smooth
non-iridescent variants by smooth iridescent culture (Carter 1967;
Heddleston et al 1964).
Biochemical Characteristics
P. multocida organisms are positive for oxidase (Carter 1984)
catalase (Cowan 1974), and indole (Breed et al 1957) and produce
nitrites from nitrates (Namioka 1978).
positive (Breed et aj. 195 /") . They ferment sugars such as glucose,
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sucrose, sorbitol and mannitol with acid, but with no gas
production. Lactose, maltose and salicin are not fermented,
whilst variable fermentation is obtained with arabinose, trehalose
and xylose (Cowan 1974). Gelatin is not liquefied (Breed et al
1957). In triple sugar iron agar,although acid is produced>no gas
or hydrogen sulphide are produced (Carter 1984). Table 1.1
describes the main criteria for the differentiation of P. multocida
from other closely related species.
Serological Characteristics
Early Attempts at Classification of P.multocida
Lignieresi (1901) suggested a "zoological classification" of the
species Pasteurella multocida, based entirely on the history of
isolation of the organism. The existence of more than one
serological group in this species was later demonstrated by several
workers employing different serological procedures (Cornelius 1929;
Yusef 1935; Rosenbusch and Merchant 1939; Little and Lyon 1943;
Robert 1947) but none of these classifications were followed up.
These are summarized in Table 1.2.
Classification of P. multocida by the Capsular Antigen
Isolates of P. multocida were later grouped into four different
types A, B, C and D on the serological specificity of the
capsular substance (Carter 1955; Namioka and Murata 1961a). Carter
a V
(1961) reported the existence of a new type, E^and eliminated the
earlier type C (Carter 1963) as it did not represent a single
important type or a group (Table 1.2).
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Table 1.1 Some basic criteria for the identification of














(a)= some exceptions reported
(b)= not as haemolytic as P.haemolytica
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Classification of P. multocida bv the Somatic Antigen
The classifications described below are based on the
lipopolysaccharides (LPS) of P. multocida. Since LPS represent the
major surface antigens of Gram-negative bacteria and most LPS are
active as endotoxins, the terms O-antigens, endotoxin and LPS are
used synonymously (Brade et al 1988).
The somatic (0) antigen (the residue left after hydrochloric
acid treatment of the cells) was the basis of this classification
(Namioka and Murata 1961a; 1961b; 1961c). Within the four
capsular types of P. multocida, eleven somatic types were
identified (Namioka and Murata 1961a; 1961b; 1961c; Namioka and
Bruner 1963; Namioka and Murata 1964). The method involved a
complex procedure of absorptions for producing type - specific sera,
and^therefore, failed to gain wide application (Table 1.2).
Another somatic serotyping system was later introduced by
Heddleston et al (1972) for fowl cholera isolates. The antigen
used was a lipopolysaccharide-protein complex similar but not
identical to endotoxin. To date sixteen serotypes have been
described using this method (Table 1.2).
Designation of Serotypes
To standardize the method of designating a serotype^Carter and
Chengappa (1981) recommended the use of a combination of Carter's
(capsular) and Heddleston's (somatic) serological classifications.
Thus, for exampleja serotype will be designated as A : 3 where A















































































































































































Distribution of Serotypes Among Animals
Strains of capsular types A and D are distributed widely with
regard to host, while most of the type B and E strains are
recovered from cattle, bison and water buffaloes (Carter 1967). An
association of somatic type and P. multocida infections in
different animals was described by Murata and Namioka (1964).
According to the earlier classification of somatic : capsular
combination, serotype 5:A occurred most commonly as a pathogen of
fowl (Namioka and Murata 1961c). Isolates of serotype 9:A were
recovered from turkeys and the most prevalent serotype from swine
was 1:A. The occurrence of a number of serotypes in several animal
species was also reported. Serotype 5:A was recovered from pigs as
well as from poultry; and 1:A, which occurred in pigs was also
recovered from mice (Namioka and Murata 1963). Isolates belonging
to either 6:B or 6:E were associated with cases of haemorrhagic
septicaemia in cattle and buffaloes (Carter 1967) .
Serotype 3:A (Heddleston : Carter) was found to be the commonest
isolate among most animal species in USA (Heddleston et al 1972;
Blackburn et al 1975). Although a similar serotype distribution
was observed among isolates of P. multocida from avian species in
Britain, in addition to serotype 3:A, serotype 1:A also appeared to
be prevalent (Curtis 1976). A higher percentage of P. multocida
isolated from rabbits belonged to type A, while few were type D (Lu
et al 1978). The prevalence of Heddleston's serotypes 3:A and 12:A
has been observed in rabbits in USA and Canada (Brogden 1980 ;Lu et
al 1983 ; Percy et al 1984). In another study 3:A was recovered
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most frequently from lungs of swine at slaughter (Pijoan et al
1983) .
Laboratory Animal Models for the Disease
Pasteurella multocida is pathogenic for a wide range of hosts.
In pathogenicity, virulence and immunological studies the
laboratory animals most commonly used are mice, rabbits, chickens
and turkeys because of their high degree of susceptibility to
experimental infection by a variety of P. multocida serotypes
(Carter 1967).
Mice
Collins (1973) studied the pattern of growth of P. multocida in
vaccinated and normal mice. The rapid multiplication of the
organism (minimum in vivo generation time 15 min) extracellularly
in the peritoneal cavity explained the high virulence of this
organism for the mouse.
However the immune response of mice to P. multocida was
different from that of chicks. Killed capsulated cells of P.
multocida induced a better immunity than non-capsulated cells in
mice. Immunity was induced by the intraperitoneal route but not by
the subcutaneous route. However, a high degree of immunity was
induced in chicks with both capsulated and non-capsulated cells of
P. multocida, regardless of the route of inoculation. The mouse
model therefore was considered to be unsuitable for the
determination of immunogenic differences among isolates of
P.multocida (Heddleston and Rebers 1969).
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Okerman et al (1979) used an 8 hour broth culture containing 10
cfu/ml to infect mice with isolates of P. multocida. Mice were
injected with 0.5 ml of a ten fold dilution of the culture broth,
mortality was recorded for 7 days and the median lethal dose (LD^^)
was calculated. Isolates originating from the septicaemic form of
pasteurellosis in rabbits were highly virulent for mice, while
those from typical snuffles}a local nasal infection,were less
virulent. They also exposed mice to an aerosol of an 8 hour broth
culture. Mortalities in mice were recorded for up to 10 days.
Highly virulent strains killed all the mice within 3 days, less
virulent ones killed 50% of mice within 9 days, while non-virulent
strains did not kill any mice (Okerman et al 1979) .
Mice were used to compare the immunogenieity of different
strains of P. multocida type A from bovine pneumonia (Abdullahi
1987). Mice were infected with 10 of P. multocida i.p
following immunization with two doses of vaccine inoculated s.c two
weeks apart.
Rabbits
Webster (1928) infected rabbits intranasally with a culture of
P. multocida (then named as Bacterium lepisepticum). During the
periods of observation, the longest being 5 months, normal
rabbits reacted in different ways to the experimental infection.
Some rabbits became either short-term or long-term carriers, some
developed snuffles of varying duration; while others developed
snuffles followed by pneumonia and signs of general infection after
a few days or a few weeks. The authors concluded that the effects
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observed depended upon the degree of resistance of the individual
animals and the virulence of P. multocida.
To determine the most effective route of inoculation of P.
multocida in order to produce pneumonic lesions in rabbits with
serotypes 3:A and 3:D, Percy et al (1986) infected rabbits by
aerosol exposure, intracerebral and intravenous inoculations. Any
til
rabbits that survived were killed on the 14 day of observation
SpjCIMSlS fronrx
and^ all animals were examined microscopically for lesions in the
lower respiratory tract. They concluded that the intratracheal
route was the best method for producing pneumonic lesions in
rabbits.
The pathogenesis of P. multocida serotype 3:A in
pasteurella-free rabbits has been studied with different doses
ranging from 3.4 x 10^ to 1.8 x 10^ organisms administered
intranasally and subcutaneously (Lu et al 1982) . The degree of
pathogenicity was dose and route dependent.
Although mice or rabbits have been widely used in these
experiments, the advantages of use of the natural host from which
P. multocida was isolated has also been advocated (Heddleston and
Rebers 1969; Penn and Nagy 1976).
Antigenic Analysis of P.multocida
Gram-negative bacteria have been defined serologically according
to the antigenic composition of capsule and cell-wall antigens.
Some strains of bacteria possess a capsule composed of
polysaccharide, while others a capsular matrix of glycoprotein
overlie the bacterial cell membrane. The cell membrane or the cell
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envelope of Gram-negative bacteria is comprised of at least three
distinct layers, namely, the inner or cytoplasmic membrane, the
peptidoglycan layer and associated periplasmic space, and the
outer membrane, which acts as a selective barrier on the exterior
surface of the cell (Smyth 1985). A complex trilaminar structure
of lipoproteins, phospholipids and lipopolysaccharides is found in
the outer membrane of Gram-negative bacteria (Figure 1.1).
A number of methods have been developed for the fractionation of
Gram-negative bacterial cell envelopes and for the separation of
inner and outer membranes, thereby allowing the isolation of outer
membrane with or without peptidoglycan (Schnaitman 1971;Osborn and
Munson 1974; Lugtenberg and Van Alphen 1983). On the other hand,
simple methods such as mild heat treatment, or extraction of
bacteria with buffers of differing pH and ionic strengths have been
used to remove and prepare the capsular substances of Gram-negative
bacteria(Hancock and Poxton 1988). The capsular and cell-wall
components isolated from P. multocida have been used to classify
them into different serological groups and to study their
serological and immunological responses in different animal
species.
Studies on the Capsular Polysaccharide of P. multocida
Extraction of type specific polysaccharide substance from the
capsule of P. multocida was described by Hoffenriech (1928) and
Pirosky (1938). Later, isolates of P. multocida were consigned
into different serological groups according to their capsular
composition (Carter 1952; Carter and Annau 1953; Carter 1955).
Fig. 1.1. The cell envelope of a Gram-negative bacterium
(Courtesy of Dr. I.R. Poxton)
LP: lipoprotein; LPS: lipopolysaccharide;










The ability of a crude capsular polysaccharide to induce protection
in both chickens and mice was reported (Yaw and Kakavas 1957). Knox
and Bain(1960) purified a polysaccharide from a saline extract of
P. multocida type 1 (Robert's) which contained fructose, mannose,
glucose and glucosamine. The crude saline extract contained
varying amounts of proteins and polysaccharides. Absorption of
rabbit and cattle immune sera with this purified polysaccharide
abolished its ability to precipitate antigen in agarose gel and
reduced but did not abolish the protection afforded by these sera
(Knox and Bain 1960). Thus the capsular antigen was important in
producing immunity to P. multocida.
Using immunodiffusion and Immunoelectrophoresis techniques, 18
soluble antigens were identified in the extracts of haemorrhagic
septicaemia(HS) strains of P. multocida (Prince and Smith 1966a).
Two of these antigens were capsular in origin and were designated
as alpha (protein) and beta (polysaccharide) which were believed to
correspond to the protein and polysaccharide antigens of Knox and
Bain (1960). Comparison of soluble extracts of P. multocida (HS
ejdtr&cfs
strain) with^ eight other Gram-negative species in gel diffusion
tests demonstrated the existence of five common antigens (Prince
and Smith 1966b). The capsular antigens, i.e. alpha and beta
described in the previous study, were not shared by any of the
other Gram-negative species tested. In another study Prince and
Smith (1966c) compared the soluble antigens of P. multocida strains
belonging to Carter's types A,B and E. Both alpha and beta capsular
antigens were type specific in Carter's type B and E strains, but
the capsular antigen alpha had some antigenic determinants which
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were non-type-specific and were shared with a non-capsular
component of other serotypes.
In a comparative study of the saline and phenol water extracts
of P. multocida type B and E, capsular polysaccharide was
recognised as the type specific antigen, while LPS was the antigen
common to both serotypes (Penn and Nagy 1974). Both extracts
contained capsular antigen and LPS in varying amounts. Saline
extract consisted mainly of capsular antigen while phenol water
extract contained mostly LPS . It was concluded that the
protection afforded by these serotypes was largely type - specific
and that the capsular polysaccharide must therefore, be a
protective antigen. The importance of the capsular antigen in the
protection of cattle has been confirmed by the successful
absorption of protective antibodies from serum raised against whole
cells of P. multocida in cattle by the purified capsular substance
of type B and E of P. multocida (Nagy and Penn 1974). Purification
of capsular antigen was felt to be essential since minor
contamination of immunizing preparations with LPS might elicit the
production of anti-LPS antibodies (Penn and Nagy 1976).The nature
of this antigen, purified by solvent fractionation was studied.
The antigen exhibited a molecular weight of approximately two
million, was heat stable, was resistant to pronase digestion, and
did not absorb light at 280 nm which suggested the antigen was not
protein in nature. These properties also suggested the antigen
would be a good candidate for inclusion in a vaccine production.
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Studies on Lipopolvsaccharide (LPS) of P.multocida
Isolation and characterization of LPS of P .multocida
A Boivin type antigen (endotoxin) was recovered from smooth and
rough variants of an avian strain of P. multocida by Pirosky
(1938). The Boivin antigen was toxic, protective, and
serologically specific. The occurrence of type specific
lipopolysaccharides containing aldoheptose sugars in P. septica (P.
multocida) was later reported by Maclennan and Rondle (1957) . This
LPS was toxic in mice, heat stable and serologically specific.
Phenol water-extracted LPS from type 1 (Robert's) P. multocida
yielded galactose, glucose, glucosamine and a heptose sugar (Bain
and Knox 1961). An Australian strain of P. multocida, which by
conventional mouse protection and haemagglutination tests was
identified as type 1, yielded an LPS with different properties.
The capsular substances adsorbed to erythrocytes for the
identification of capsular types were later recognised as LPS (Bain
and Knox 1961; Carter and Rappay 1963).
LPS isolated from non-capsulated avirulent mutants of two fowl
cholera strains of P. multocida were immunogenic and toxic in
chickens (Heddleston et al 1966). Intravenous injection of 0.16 mg
amounts of LPS produced clinical signs in chickens similar to those
observed in acute fowl cholera. Similar antigens were also
isolated from virulent, capsulated, haemorrhagic septicaemic
strains (Rebers et al 1967). A comparative study of the free
endotoxin and Westphal-type LPS of capsulated and non-capsulated
strains of P. multocida revealed that the free endotoxins readily
induced antibody formation and active immunity, but the LPS did
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not (Rebers and Heddleston 1974) .
study was obtained by washing
formalinized saline.
The free endotoxin for this
agar-grown cells with cold
Structure of LPS
Enterobacterial LPS consist of three regions which can be
distinguished chemically, biologically and genetically. These
three regions are the O-specific side chain, core oligosaccharide
and lipid A (Figure 1.2). Mutants with a genetic defect in the
biosynthesis of complete LPS, and containing incomplete LPS which
lacks the O-chains, or O-chains and part of the core have been
described (Galanos and Luderitz 1984 and Brade et al 1988).




Fig. 1.2. Diagrammatic representation of lipopolysaccharide
(Poxton and Arbuthnott 1990) .
Chemical and physical analysis of LPS of 13 serotypes of P.
imiltocida (Heddleston's) showed that all LPS contained glucose,
2-keto-3 deoxyoctonate and heptose, D-glycero-D-mannoheptose and
L-glycero-D-mannoheptose (Rimler et al 1984).
Characterization of LPS from five isolates of P. nmltocida from
rabbits by SDS-PAGE (silver stained), Western blotting and ELISA
revealed that the LPS of these isolates contained two types of
antigens, a non-specific and a sero-specific antigen. The LPS of
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four isolates each had a different sero-specific antigen. The
non-sero- specific antigen was expressed in two isolates and was the
only demonstrable LPS antigen in one other isolate. The LPS of
these isolates resembled those of semi-rough strains of
enterobacteria (Manning et al 1986) .
Immunogenicity of LPS
Loss of immunogenicity of whole cells and free-endotoxin on
treatment with 50% phenol indicated the requirement for the
induction of immunity of a protein component in each. An
LPS-protein complex was, therefore, postulated to be present in
the endotoxin, the immunologic specificity being determined by the
carbohydrate components of the LPS and the protein being required
for induction of immunity (Rebers and Heddleston 1974; Heddleston
and Rebers 1975). Fractionation of a culture supernate of P.
multocida with ether resulted in a "glycoprotein-like" preparation
while phenol provided a "LPS-like" preparation. The fraction
extracted by ether was an excellent immunogen in mice and phenol
extraction destroyed the immunogenicity of the supernate
(Srivastava and Foster 1977). An immunogenic fraction of a saline
extract of P. multocida consisted chiefly of a high molecular
weight protein-carbohydrate complex (Ganfield et al 1976).
Isolation of an immunogenic complex of protein-LPS from a saline
extract of P. multocida in turkeys was also reported by Syuto and
Matsumoto (1982).
Comparison of the Heddleston's heat stable antigen (1972) and
the Westphal type LPS of P. multocida in an agar-gel diffusion
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precipitin test indicated that the major component of the heat
stable antigen responsible for the type specificity was LPS
(Brogden and Rebers 1978). An LPS preparation that was free of
capsular antigen as confirmed by an agar-gel diffusion precipitin
test was not immunogenic in mice and rabbits when compared to
formalinized bacteria (Schmerr and Rebers 1979) . Similarly both
purified and crude LPS were able to induce protection in chickens
but not in mice and rabbits (Rebers et al 1980). Purified LPS in
this study was obtained by digestion of crude LPS with
deoxyribonuclease and ribonuclease enzymes followed by buoyant
density gradient centrifugation in caesium chloride. Rebers et al
(1980) observed that serum produced against the purified LPS in
chickens had a stronger serologic reaction and was more effective
in passive protection experiments in chickens.
LPS of serotypes 2 and 5 were found to be antigenically similar
when examined by the passive haemagglutination test and also
antisera against purified serotype 2 LPS passively immunized 6 of
10 poults against the serotype 5 strain. The LPS of serotype 5 of
fowl cholera and serotype 2 of haemorrhagic septicaemia strains of
P. multocida have similar chemical structures (Rimler et al 1984).
Similar cross-reactions between LPS of serotypes 4 and 12 of P.
multocida of rabbit origin in an ELISA indicated that the LPS of
these two serotypes were the common shared antigen (Cary et al
1984).
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Studies on Protein or Protein Complexes of P. multocida
Bain (1955) employed potassium thiocyanate (KSCN) to extract P.
multocida type 1 (Robert's). Fractionation of the KSCN extract
gave two components; a protective protein-polysaccharide complex
and a polysaccharide that behaved as a hapten. A crude KSCN
extract from P. multocida type 1 (Robert's) consisting of a
protein-carbohydrate complex was immunogenic and non-toxic to mice
given in 1 mg amounts i.p, while a sodium chloride extract
consisting of a protein- carbohydrate complex was toxic to mice at
doses as low as 42 ug i.p (Mukkur and Nilakantan 1972). In another
study , KSCN extract of P. multocida serotype 3 (Heddleston) of
avian origin was found to be immunogenic in chickens against the
homologous as well as against one heterologous strain (Gaunt et al
1977) .
Immunization of calves with KSCN extract of P. multocida type A
resulted in production of antibodies which were agglutinating,
haemagglutinating and bactericidal to both P. multocida and P.
haemolytica (Mukkur 1977). Treatment of this extract with
proteolytic enzymes like papain, trypsin, pronase and proteinase
k, or heating at 56°C to 121°C destroyed its immunogenicity,
suggesting that the important immunogenic determinants in the
extracts were protein in nature (Mukkur and Pyliotis 1981).
Different fractions obtained by gel filtration and
ultracentrifugation of KSCN extract expressed varying levels of
immunogenic activity in mice, which were significantly less than
that of the crude extract. These were therefore a multiplicity of
protective antigens associated with P. multocida and the
synergistic interaction between them (Mukkur et al 1982).
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A ribosomal fraction, obtained after disruption of P. multocida
cells in a french pressure cell, protected chickens and mice (Baba
1977). Further studies on ribosomal fractions indicated the
presence of a ribosomal-LPS mixture, in which ribosomes served as
immunomodulators or as adjuvant while LPS induced protection in
chickens (Phillip et al 1981; Phillip and Rimler 1984).
Examination of cytoplasmic and cell envelope associated antigens
of P. multocida serotype 1 (Heddleston's) by crossed
immunoelectrophoresis demonstrated at least 55 cytoplasmic and 19
cell envelope associated antigens (Bhasin and Lapointe-Shaw 1980) .
This would indicate that humoral and/or cell-mediated immune
responses elicited by such crude preparations as culture filtrate,
cell wall, cytoplasm and other complex antigen preparations
extracted from whole cells of P. multocida were probably composite
reactions to more than one antigen. They also reported the
capacity of the formalin-killed whole cells of P. multocida to
elicit an immune response to internally situated soluble antigens.
This indicated that P. multocida cells were relatively fragile and
disintegrated readily in vivo to expose internal antigenic
components.
SDS-PAGE Analysis of P. multocida Antigens
Lugtenberg et al (1984) suggested the use of the SDS-PAGE
pattern of LPS and cell surface proteins instead of the guinea-pig
skin test to predict pathogenicity of strains of P. multocida
isolated from atrophic rhinitis in swine. Characterization of the
cell envelope protein patterns of 34 isolates of P. multocida from
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swine revealed three distinct patterns and the electrophoretic
mobility of a major protein "H" in the range of an approximate
molecular weight of 36kDa was used to differentiate them into
groups according to their cell envelope protein pattern (Lugtenberg
et al 1984; Lugtenberg et al 1986). Recognition of the same
protein in a doublet by an immunoblot with sera raised against
whole cells of P. multocida in pigs indicated that they were among
the major surface-exposed proteins. Following electrophoretic
separation of P. multocida cell envelope, the gels were reacted
with immune sera from pigs in a gel-radioimmunoassay. An antigen
which appeared as a smear with a relatively low electrophoretic
mobility was considered to be an immunogenic complex consisting of
protein 'H' and LPS (Lugtenberg et al 1986).
In contra-distinction to the studies with the swine isolates of
P. multocida the outer-membrane protein pattern of bovine P.
multocida type A did not differentiate the isolates into
serological groups or correlate with their pathogenicity in mice.
Also there were no differences in the outer-membrane patterns among
the typical P. multocida type A, atypical P. multocida type A and
taxon 13 strains (Abdullahi 1987). On the other hand,
outer-membrane protein profiles of isolates of P. multocida
belonging to serotypes 1, 3 and 12 (Heddleston's) on SDS-PAGE
differed from one another and these differences may have accounted
for the lack of heterologous protection among isolates of in vitro
grown P. multocida ( Corbett et al 1983; 1984).
Sera raised against a KSCN extract of P. multocida serotype 3:A
in rabbits were used to identify the outer-membrane immunogens by
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radioimmunoprecipitation and Western blotting (Lu et al 1988a). Of
the 18 proteins recognised by these sera, the major antibody
response was directed against a 27,000 molecular weight (27kDa)
outer-membrane protein together with 37.5, 49.5, 58.7 and 64.4kDa
outer-membrane proteins. Absorption of the immune sera with the
intact P. multocida organisms resulted in a significant reduction
of antibody activity directed against these proteins, especially
the 37.5kDa. Elution of an antibody against the 37.5kDa immunogen
from the surface of the P. multocida organisms indicated this
immunogen was exposed on the cell surface and was accessible to
antibody (Lu et al 1988a). A monoclonal antibody to this 37.5kDa
protein recognised 36 of 153 rabbit clinical isolates and was
distributed among the major somatic types 3, 10, 12, and 15 and
also capsular types A and D, suggesting the possible use of this
outer-membrane protein as a vaccine (Lu et al 1988b) .
Vaccines
Pasteur in 1880 produced an attenuated vaccine from live
cultures from cases of fowl cholera by prolonged growth on
artificial media. These protected fowls from subsequent infection.
This method, however, was not reproducible. Since that time the
search for new vaccines to control pasteurellosis has continued.
Bacterins/Chicken Embryo Vaccine
Phenol-killed broth-grown bacterins (Hilbert and Tax 1938) and
chicken embryo vaccines (Carter 1950) have been used to control
fowl cholera in ducks. Immunogenicity of the chicken embryo
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vaccine was found to be superior to the Hilbert and Tax's
phenol-killed broth bacterin and other commercial bacterins as it
protected the largest percentage of ducklings against infection
with virulent P. multocida cultures (Dougherty 1953).
Adjuvant Vaccines
With the introduction of adjuvants a considerable improvement in
the efficacy of the bacterins has been observed (Freund and Bonanto
1944). The value of light mineral oil or water-in-oil emulsion
vaccines for enhancing and prolonging antibody response to bacteria
had been stressed by Freund et al in 1948. This was supported by
the findings of Bain (1954) when cattle immunized with conventional
formalin-killed bacterin succumbed to infection while those
immunized with bacterin in oil-adjuvant were immune.
Later, the oil adjuvanted vaccines were subjected to detailed
studies by many research workers (Vancheswara et al 1955; Bain
1959; Dhanda and Lall 1958; Dhanda et al 1960; Mall and
Nilakanthan 1971). Because of its efficacy, safety and stability,
the oil adjuvant vaccine was recommended for the control of
haemorrhagic septicaemia (Bain et al 1982).
An oil adjuvant vaccine containing killed whole cells of P.
multocida induced better immunity in chickens than either an
aqueous-suspended, alum-precipitated, chicken embryo, or a broth
bacterin or an adjuvanted vaccine of capsular substance (Heddleston
and Hall 1958). Heddleston and Reisinger (1960) showed that by
increasing the concentration of bacterin and aluminium hydroxide
gel in the aluminium hydroxide adsorbed, killed fowl cholera
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vaccine, a much longer duration of immunity of at least 52 weeks
could be attained.
Bacterins prepared from P. multocida type A killed by formalin
and B-propiolactone conferred protection in birds which lasted five
months after vaccination, regardless of the differences in the
killing agent (Chute et al 1962). In contrast, a heat-inactivated
bacterin containing type A P. multocida strain induced better
immunity in turkeys than formalinized bacterins irrespective of the
kind of adjuvant used(Bhasin and Biberstein 1968) .
Induction of Cross - Protection
P. multocida shows a marked antigenic diversity and the host
environment apparently influences the development of protective
antigens (Heddleston and Rebers 1972;1974). Use of host grown P.
multocida to study the immune response in chickens and turkeys has
therefore been considered as important. Bacterins prepared from P.
multocida grown in the tissues of birds demonstrated homologous as
well as heterologous protection whereas a bacterin prepared with
bacteria grown on dextrose starch agar failed to induce
heterologous protection revealing that P. multocida produce a wider
spectrum of antigens in vivo rather than in vitro (Heddleston and
Rebers 1972). The cross-immunity induced in turkeys was
host-specific, as the antigen responsible was produced in turkeys,
only when P. multocida was grown in embryonating turkey eggs and
not when it was grown in embryonating chicken eggs or in mouse
tissues (Heddleston and Rebers 1974). The cross-protection
afforded by a bacterin prepared with P. multocida originating from
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infected turkey or chicken tissue was lost when P. multocida in the
bacterin were replaced by repeatedly subcultured cells (Rebers and
Heddleston 1977). Crude liver homogenates as well as infected
blood from turkeys which died of experimental fowl cholera produced
by serotypes 1 or 3 of P. multocida induced cross-protection. In
contrast to this, neither the washed bacterial cells nor
bacteria-free plasma from infected turkeys induced significant
cross-protection (Rimler et al 1979). Most of the cross-protection
factors were bound to the bacterial cell and could be easily
removed by simple washing.
Rimler et al (1979) searched for appropriate conditions under
which P. multocida could be grown in vitro that might have had the
equivalent antigenic content to induce protection and
cross-protection as live attenuated vaccines. It was found that
B-vitamins enhanced this ability while certain inorganic salts (e.g
(NH^^SO^, KP^PO^, NaHCO^, MnSO^ ,FeSO^) repressed it. Plasma of
normal turkeys contained a compound that was responsible for
expression and maintenance of this heterologous protection. Under
in vitro conditions growth temperature also influenced expression
of cross-protecting antigens which was enhanced at 41.5°C and
repressed at 37°C. If grown and maintained under appropriate
conditions, in vitro grown P. multocida can be as immunogenic as
tissue and live attenuated vaccines. Rimler et al (1979)
successfully maintained the cross protection factors of avian
P. multocida in vitro through at least nine serial passages by
growing the organisms in media containing 50% turkey blood.
Separation of P. multocida organisms from infected turkey blood has
27
been carried out satisfactorily by density gradient centrifugation
in sucrose. Complete lysis of host grown P. multocida by
freeze - thawing and treatment with lytic solutions (ie.DNAse,
hyaluronidase, EDTA or Triton X-100) have not influenced the
ability of the lysate to induce homologous as well as heterologous
protection (Rimler and Rhoades 1981).
The level of protection (either homologous or heterologous)
induced by a vaccine varied with the quality of the particular
immunogens that have been incorporated in the vaccine (Rimler and
Rhoades 1981). Differential centrifugation and density gradient
centrifugation were employed to separate the cross-protection
factors from the complete lysate of P. multocida (Brogden and
Rimler 1982a). Homologous and heterologous immunizing activities
in
were found both in the soluble and^the pelleted portions of the
lysate. The immunogenic activity of the cross-protection factors
was greatly reduced after trypsin treatment and was completely
abolished after pepsin treatment, but was not affected by heating
at 56°C for 1 hour. This suggested that the antigen was protein in
nature (Brogden and Rimler 1982a). Examination of the pellet
obtained after centrifugation of the complete lysate by electron
microcopy revealed it consisted of small membrane vesicles, ranging
in size from 0.05 urn to 1.0 um. These vesicles also had a
characteristic trilaminar membranous appearance, similar to those
reported from other Gram-negative bacteria treated similarly
(Brogden and Rimler 1982b). An attempt has been made to release
protein from the membrane vesicles that may contain
cross-protection factors. Vaccines made from combining solubilized
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membrane vesicles with complete lysate supernatant fluid produced
various degrees of protection against heterologous infection in
turkeys (Brogden and Rimler 1983). Vaccines containing membrane
vesicle material solubilized by KSCN or sodium lauroyl sarcosinate,
when combined with complete lysate supernate, protected turkeys as
did complete lysate. The authors concluded that the
cross-protection factor of turkey-grown P. multocida was expected
to be an antigen that turkeys would respond to during a natural
infection.
Vaccination of Mice with P. multocida
Of the vaccines which contained formalin-killed, heat-killed
whole cells, LPS and capsular substance of bovine P. multocida type
A in adjuvant, only formalin and heat killed whole cell vaccine
induced protection in mice (Abdullahi 1987). However, the antigens
responsible for this protection could not be identified by the
techniques such as Enzyme-Linked Immunosorbent Assay (ELISA),
immuno-blotting and fused rocket-Immunoelectrophoresis.
Vaccines prepared from the tissues of mice dying of
pasteurellosis induced by four different capsular serotypes (A, B,
D and E) of P. multocida provided complete homologous protection
with all serotypes and complete cross-protection between the
haemorrhagic septicaemia serotypes B and E. Although this complete
heterologous protection between serotypes B and E correlated with
somatic antigen specificity, the homologous protection observed in
other serotypes demonstrated involvement of other antigens (i.e
capsular or complex protein) besides serotype specific ones (Rimler
and Boycott 1979).
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The possible existence of a common immunizing antigen between
P. multocida type A and D had been revealed by active immunization
and passive protection experiments (Cameron et al 1978; 1980).
Vaccines containing more than four strains of P.multocida failed to
induce protection even against the vaccinating strain (Cameron and
Bester 1983). However, hyperimmune sheep antiserum to a type D
strain protected mice against infection with a number of type A
strains. Later, an alum-precipitated vaccine was formulated
incorporating this type D strain and a selected strain of type A
(Cameron and Bester 1984). The vaccine induced production of
antibodies in sheep that conferred homologous protection in mice as
well as affording heterologous protection against a variety of type
A and D strains and a number of untypable strains of P. multocida.
These studies suggest that P. multocida express an antigen that
could be common to more than one serotype.
Live Attenuated Vaccines
Any killing of organisms for purposes of vaccine production may
result in loss of important immunogens (Chengappa et al 1980). A
live vaccine may reduce or eliminate this loss of protective
immunogens. A live P. multocida vaccine administered in drinking
water induced immunity against heterologous infection in turkeys
(Maheswaran et al 1973; Heddleston et al 1975; and Coates et al
1977). A wild type P. multocida type A isolated from a rabbit
suffering from respiratory disease was used to produce a
streptomycin-dependent mutant and the rabbits were vaccinated with
8 8
either 4.5 x 10 or 5.0 x 10 organisms/ml subcutaneously or
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intranasally (Chengappa et al 1980) . This vaccine elicited
complete protection against homologous infection with virulent wild
type P. multocida . A similar vaccine incorporating live
streptomycin-dependent P. multocida 3:A (Heddleston's) and live
streptomycin-dependent P. haemolytica Al induced better protection
than the commercial bacterin when tested against a virulent
homologous infection in calves (Catt et al 1985) . In another study
immunization of rabbits with a streptomycin-dependent strain of
P. multocida type 12:A (Heddleston) elicited detectable antibody
production to somatic antigens of both 12:A and heterologous strain
3:A (Percy et al 1985).
P. multocida (B:3,4) isolated from a fallow deer in England
which was less virulent for calves was used as a live vaccine to
protect calves against experimental haemorrhagic septicaemia (B:2)
infection (Myint et al 1987).
Subcellular Components of P.multocida as Vaccine
Although the use of bacterins and live attenuated vaccines are
generally effective against P. multocida infection, the disease
still occurs in vaccinated animals. Therefore, attempts have been
made to identify subcellular components of P. multocida that would
induce protection, in the hope of developing vaccines of higher
potency than those currently in use.
Vaccines Containing Capsular Polysaccharides
A heat-extracted crude capsular polysaccharide has been used to
protected mice against heterologous infection (Carter and Annau
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1953) and chickens and mice against a homologous infection of
P. multocida (Yaw and Kakavas 1957). Dhanda (1958) reported that of
the five different fractions (carbohydrate-protein, protein,
toxin, LPS and protein-free capsular carbohydrate ) obtained after
treatment with different solvents, the protein-free capsular
carbohydrate and the LPS fractions were not immunogenic in mice,
chickens and rabbits. However, Bain (1958) found both LPS and
protein-free capsular polysaccharide fractions were to be
immunogenic in mice and cattle.
A vaccine of emulsified cell-free capsular extract of
P. multocida induced effective immunity against a virulent
infection of P. multocida in chickens for at least 25 weeks
(Heddleston and Hall 1958). A capsular antigen purified from a
crude saline extract of type B and E P. multocida provided active
and passive protection in mice (Penn and Nagy 1974; Nagy and Penn
1974). Absorption of anti-whole cell bovine serum by the purified
capsular antigen, eliminated its protective ability in mice
against a homologous infection. The capsular antigen was therefore
considered to be the protective antigen in cattle. Although the
capsular antigen was protective in cattle in aluminium-hydroxide
gel adjuvant, it was poorly immunogenic in rabbits (Penn and Nagy
1976) .
The immunogenicity of capsular polysaccharide was also
investigated by Kodama et al (1981). Although the crude capsular
antigen extracted from P. multocida provided protection in turkeys
against homologous infection, the purified polysaccharide antigen
obtained by treating the crude capsular antigen with
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cetylpyridinium chloride was non-immunogenic. The crude capsular
antigen was a polysaccharide-protein complex of which the
immunogenieity was lost by acid hydrolysis but not affected by
treatment with chloroform, trypsin or heat. The apparent
stability of this crude capsular antigen was considered as an
advantage in vaccine production (Kodama et al 1981) .
A protein-carbohydrate antigen purified from the crude capsular
substance by chromatography induced the formation of antibodies in
rabbits and turkeys (Syuto and Matsumoto 1982) . The same antigens
isolated from serotypes 1 and 3 (Heddleston) P. multocida type A,
although possessing similar physico-chemical properties, were
found to be immunogenically distinct from each other as analysed by
the agarose gel diffusion precipitation test and cross-protection
experiments in turkeys (Kajikawa and Matsumoto 1984).
Vaccines Containing LPS or LPS/Protein Complexes
An antigen which resembled endotoxins, extracted with cold
formalinized saline from smooth and rough variants of P. multocida
protected birds against fowl cholera infection(Heddleston et al
1966) . Using the same method an LPS-protein complex was isolated
from a virulent, encapsulated strain of P. multocida, which in 15
ug amounts protected mice against a homologous infection (Rebers et
al 1967). Treatment of the LPS with phenol destroyed the protein
moiety of the LPS-protein complex rendering it non-immunogenic
(Heddleston and Rebers 1975 and Schmerr and Rebers 1979).
A KSCN extract of P. multocida serotype 3 (Heddleston's)
protected chickens against homologous as well as one heterologous
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strain (serotype 1). Emulsification of the extract in Freund's
incomplete adjuvant (FIA) increased its efficacy. A component in
the KSCN extract of the two serotypes were found to be identical in
the agar-gel diffusion precipitation test (Gaunt et al 1977) .
Cross-protection between P. multocida type A and P. haemolytica
serotype Al in mice immunized with KSCN extract of P. multocida
suggest a sharing of common immunogens between the two species
(Mukkur 1977).
In calves too, this KSCN extract produced higher antibody
responses when it was inoculated with FIA than those inoculated
with Tris-saline buffer (Mukkur 1978) . A protein-LPS complex
isolated from KSCN extract of P. multocida was found to be more
immunogenic than the crude extract in mice (Ryu and Kaeberle 1986) .
Studies carried out in rabbits with the KSCN extract of
P. multocida serotype 3:A provided significant protection against
homologous experimental infection, and this vaccine appeared to be
safe when inoculated by the intranasal or the intramuscular
routes (Lu et al 1987a).
A vaccine containing a ribosomal fraction of P. multocida
serotype 8:A (Heddleston) protected mice and chickens against
virulent, homologous infection (Baba 1977). He confirmed that pure
LPS is not an immunogen in mice and suggested that the protective
power of LPS-protein complex observed in previous studies
(Heddleston et al 1966, Rebers and Heddleston 1974) could be due
to the presence of ribosomes as contaminants in the preparations.
The requirement of LPS in ribosomal vaccines for the development of
protection was confirmed by Phillip and Rimler (1984). The
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addition of a serotype 1 (Heddleston) LPS to LPS-free affinity
purified ribosomes obtained from P. multocLda resulted in a vaccine
that protected against a homologous infection but replacement of
1:A LPS with heterologous serotype 5:A LPS in LPS-free affinity
purified ribosomes did not protect chickens against a virulent
serotype 1 infection, but produced antibodies to serotype 5. This
indicated that protection was conferred by specific LPS. The
protective ability of the ribosomal vaccine was conserved when
ribosomes were substituted by other fungal or bacterial
(Aspergillus fumigatus, Brucella abortus) ribosomes but not when
replaced by chicken liver ribosomes, revealing that ribosomes or
their components have to be foreign to the host to potentiate LPS
immunogenicity (Phillip and Rimler 1984).
Growth of P.multocida under Iron Restriction Conditions
One common and essential factor in all infections is the ability
of the invading pathogen to multiply successfully in host tissues.
This ability is known to be greatly influenced by the availability
of iron. Most of the iron in the body of mammals is found
intracellularly as ferritin, haemosiderin or haem and
extracellularly in serum attached to high-affinity iron-binding
proteins, transferrin in blood and lymph and lactoferrin in
external secretions and milk. A related protein called
ovotransferrin occurs in avian egg white (Griffiths 1985) . The
amount of free iron available to bacteria therefore is extremely
small. Even with this restriction, those bacteria which multiply
successfully and establish an infection must be able to develop
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mechanisms for assimilating protein-bound iron or for acquiring it
from liberated haem. Most micro-organisms have been found to
produce specific high-affinity iron-binding compounds termed
siderophores, which chelate ferric ions into an assimilable form
(Barclay 1985) . When the bacteria have to adapt to a severely
iron-restricted environment by producing siderophores they also
produce a number of high-molecular mass outer-membrane proteins.
In E. coli these proteins are usually designated according to their
relative molecular masses 83, 81, 78 and 74kDa proteins.
Iron regulated outer-membrane proteins were demonstrated when
E.coli 0111 was grown in broth containing ovotransferrin or in vivo
during infection (Overbeeke and Lugtenberg 1980). Other pathogenic
bacteria have also been shown to produce extra outer-membrane
proteins when grown under iron-restricted conditions in vitro
(Griffiths 1985). An outer-membrane protein of Pseudomonas
aeruginosa described as ferripyochelin-binding protein (FBP) was
involved in iron acquisition when complexed with the Pseudomonas
siderophore, pyochelin. It was detected as a major outer-membrane
protein in iron-starved, glucose grown cells (Sokol and Woods
1983) . Proteus mirabilis and Klebsiella pneumoniae isolated
directly from the urine of patients with urinary tract infection
expressed extra high molecular mass outer-membrane proteins. These
proteins corresponded to proteins that were induced in the
iron-depleted medium and disappeared when the organisms were grown
in iron-rich medium in vitro (Shand et al 1985) . Recognition of
these proteins by the patient's own serum revealed that these
proteins were highly antigenic.
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A fish pathogen, Vibrio anguillarum, also produced an
outer-membrane protein (86kDa) under iron restricted conditions
(Actis et al 1985). The role of outer-membrane proteins in the
immune mechanisms were studied in certain instances. Anti-FBP
antibodies were found to be opsonic and protected mice against
P.aeruginosa infection (Sokol and Wood 1985). Passive immunization
of turkeys with antibodies to iron-regulated outer-membrane
proteins of E.coli protected them from experimental colisepticaemia
(Bolin and Jensen 1987) .
Recent studies on P. multocida indicated that iron deprivation
induced four new outer-membrane proteins of approximate molecular
weight 33, 60 65 and 71kDa and decreased the presence of
outer-membrane proteins 48k and 58kDa as compared to iron replete
cells. Active immunization of mice with these outer-membrane
preparations provided homologous protection but not heterologous
protection (Corbett et al 1985). They also reported that no
phenolate or hydroxymate-type siderophores could be detected in the
supernates of iron-starved cells. Secretion of a siderophore into
the culture medium by P. multocida type A strains under conditions
of iron deprivation was first reported by Hu et al (1986). This
siderophore with a novel chemical structure was given a trivial
name "multocidin". As P. multocida is known to be a very virulent
organism to many animal species, apart from producing
siderophores, it must produce outer-membrane proteins to
assimilate iron from bound proteins of the host. These proteins if
incorporated into vaccines may provide a higher level of immunity
in animals against homologous as well as heterologous infection.
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Evidence suggested that P. multocida grown in vivo in turkeys
produced better immunogens which induced homologous and
heterologous protection than in vitro grown cells which conferred
homologous protection only (Heddleston and Rebers 1972; 1974;
Rebers and Heddleston 1977 and Rimler et al 1979) .
Immunity
Effector mechanismCs) of Immunity to P.multocida Infection
Unvaccinated laboratory animals (rabbits, mice and turkeys) are
highly sensitive to many strains of P. multocida (Carter 1967). The
natural hosts (cattle and birds) seem to be incapable of mounting
any resistance to the progressing infection, even when very small
numbers of virulent organisms are introduced into the tissues. This
results in a highly lethal infection involving the lungs, liver,
spleen and blood (Collin 1973). Attempts to increase host
resistance by active immunization is practiced as a routine. As
most avian or bovine strains of P. multocida are also virulent for
mice, this host has been used for the experimental assay of
P. multocida vaccines (Murata et al 1964; Heddleston and Rebers
1969; Rimler and Boycott 1979). In such protection tests the
development of acquired resistance can be inferred from an 80% or
better survival of the vaccinated mice in the face of a more than
80% mortality in the unvaccinated controls. The mechanism involved
in the expression of this acquired resistance seems to be humoral
in nature, since passive protection can readily be achieved by
inoculating hyperimmune sera (Carter 1967; Collins 1977; Nathanson
et al 1980 and Lu et al 1987a). However, the exact mode of action
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of the opsonic, antitoxic or bactericidal antibodies in overcoming
infection is still not clear (Collins 1973; Woolcock and Collins
1976) .
Phagocvtosis
In P. multocida infection, phagocytosis of pathogenic organisms
by cells of non-immune, susceptible animals is slight. However,
there is evidence for opsonic action by specific antibodies both in
vivo and in vitro correlating with enhanced protection against
experimental infection (Carter 1964; 1967 and Collins 1973). On
the other hand, in passive protection experiments, inclusion of
antibodies within the peritoneal cavity did not always result in
the immediate inactivation of the bacterial population, but it
limited the free spread of the organisms from the initial site of
infection into the blood (Bain et al 1982; Woolcock and Collins
1976). Also it was evident that the immune process did not
directly involve the mononuclear cellular defences but only
polymorphonuclear leukocytes (Woolcock and Collins 1976; Collins
and Woolcock 1976). Failure of specific antibody and complement to
kill or even inhibit the growth of P. multocida and the apparent
inability of specific antibody to enhance granulocyte phagocytosis
in vitro indicated that antibody may not have a significant role in
controlling invasive infections in rabbits (Hoffing et al 1979).
Resistance of P. multocida to granulocyte phagocytosis was found
only in some virulent strains.
Rush et al (1981) reported that the virulence factors of
P. multocida type A, which promoted resistance to rabbit
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polymorphonuclear leukocyte phagocytosis and killing, were not
associated with the hyaluronic acid capsule. In another study the
resistance of P. multocida type A to rabbit polymorphonuclear
leucocyte was attributed to the presence of hyaluronic acid capsule
(Maheswaran and Thies 1979; Anderson et al 1984). In contrast to
these findings, three isolates of P. multocida with substantial
differences in virulence (LD^q) for mice were all inactivated by
normal mouse peritoneal macrophages provided that the organisms
were opsonized with specific hyperimmune serum (Collins et al
1983). Ryu et al (1984) reported that the inhibitory factor
present in type A P. multocida capsule which determined its effect
on polymorphonuclear leukocytes was not hyaluronic acid but was a
heat stable, saline extractable capsular material of molecular
mass greater than 300kDa. In another study, the morphology of
P. multocida was attributed to the differences observed in the
association of bacteria with bovine alveolar macrophages and
killing of bacteria (Ashfaq and Campbell 1986) . In this study
specific antibody and/or complement enhanced the association of the
rough strain of P. multocida with macrophages and also increased
the killing effect of macrophages on the bacteria, while in a
smooth strain of P. multocida only association of bacteria with
macrophages was observed. The role of specific antibodies in the
phagocytosis of P. multocida is not clear as there are many reports
of non-immune adherence of pasteurellae to polymorphonuclear
leukocytes or macrophages and intracellular killing of P. multocida
(Rush et al 1981; Anderson et al 1984 and Ashfaq and Campbell
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1986). Very little is known about the importance of complement in
both the opsonization of P.multocida and in the stimulation of
intracellular killing.
Bactericidal Activity of Serum
Bactericidal antibodies to P. multocida have not been
conclusively demonstrated (Carter 1967). Although it is accepted
that immunity to P. multocida is humoral in nature, which
mechanism(s) operate however, remains unanswered. Exposure of many
strains of Gram-negative bacteria (i.e, E. coll, Salmonella) to
serum results in loss of viability and even in destruction of the
bacterial cell. The role of complement and its activation via the
classical or the alternative pathways by Gram-negative bacteria is
well known. The activation of complement via the classical pathway
requires recognition of bacterial surface antigens by certain
antibody classes whereas activation of the alternative pathway can
be initiated in the absence of antigen-antibody interactions, by
certain structural characteristics of the cell surface (Taylor
1983) . In a complement-dependent bactericidal assay the relative
importance of IgM and IgG as bactericidal antibodies were
emphasized (Schulkind et al 1972) . In the sera of mice that were
successfully immunized with a KSCN extract of P. multocida against
an experimental infection, bactericidal activity was found to be
localized in the IgM and IgG fractions (Mukkur 1979). Clinical
isolates of P. haemolytica Al were shown to be susceptible to
bactericidal activity of antibodies in adult cattle sera when these
antibodies were combined with complement (MacDonald et al 1983) .
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Presence of bactericidal antibodies in the sera and lung washings
of lambs that recovered from P. haemolytica A2 infection was
demonstrated by Sutherland (1988). The presence of these
antibodies correlated with the resistance of lambs to P.haemolytica
infection. On the other hand, resistance of clinical isolates of
both P.haemolytica and P.multocida to serum was also reported which
could be attributed to the virulence of these organisms (Blau et al
1987). Although there are indications as to the susceptibility of
P. multocida to serum killing which operates via the classical
pathway (Griffiths 1974; Mukkur 1979 and Blau et al 1987) very
little is known on this aspect of mechanism(s) of immunity to
P. multocida .
Measurement of humoral immunity to P.multocida
A number of procedures have been developed for the measurement
of humoral immunity to P. multocida. These are: the agglutination,
haemagglutination, serum bactericidal and incuse P«&Sprotection
tests (Carter 1967). Carter (1964) found a correlation between
haemagglutination titre to P. multocida and the passive protection
capacity of anti-pasteurella serum in mice. Protection tests in
mice and the indirect haemagglutination test to measure antibodies
to type E and B P. multocida in cattle and buffaloes have been
extensively used in many countries (Perreau et al 1964; Bain et al
1982; De Alwis et al 1986; Wijewardana et al 1986). Failure to
determine the immune status of chickens and turkeys to P. multocida
by the passive protection tests in mice, the agar-double diffusion
test or serum plate-agglutination test was reported by Heddleston
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and Watko (1965). The antibody response of the vaccinated birds
detected by the haemagglutination test had no bearing on the immune
status of the birds (Bhasin and Biberstein 1968). These two studies
reflected that protective antibodies in birds were not detected by
the usual serological methods. The indirect haemagglutination test
was the best indicator of the immune status of non-vaccinated
sheep, while the agar agglutination test was found to be the best
for measuring the immune status of vaccinated sheep (Dua and
Panduranga 1978).
It is evident from this review of the literature, that the
antigens involved in protection against P. multocida infection have
not been well defined. As a result currently- available vaccines
give varying degrees of protection and the disease still remains as
a problem in many species of animals. The experiments described in
this thesis were therefore aimed at identifying antigens which
would give a better immunity, and the possible effector mechanisms
of immunity in P. multocida in mice. The objectives were therefore:
a) to study the outer membrane proteins of P. multocida type A
of bovine origin grown in in vivo and in vitro under iron
restricted conditions.
b) to evaluate the immune response of mice to cells grown in
/
in vivo and in vitro under iron restricted condit'ons.
c) to study the effector mechanisms of immunity to P.
multocida in mice.
d) to produce and characterize monoclonal antibodies against
type A P. multocida with a view to identifying the protective
cell-surface antigens involved in P. multocida.
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CHAPTER 2
General Materials and Methods
2.1 Media for Isolation and Cultivation of P. multocida
2.1.1 Blood Agar with 5% Sheep Blood
Dehydrated blood agar base 40g (Gibco) was suspended in 1
litre of distilled water and sterilized by autoclaving at 121°C
for 15 min. Sterile sheep blood 50ml, collected in 4% citrate,
was added after cooling the medium to between 45°C and 50°C and
the mixture dispensed in 20ml volumes aseptically into sterile
petri dishes.
2.1.2 Dextrose Starch Agar (PSA)
Dehydrated DSA 65g (Gibco) was suspended in 1 litre of
distilled water and sterilized by autoclaving at 121°C for 15
min and 25ml volumes poured into sterile petri dishes.
2.1.3 Nutrient Broth (NB)
This was prepared by dissolving 25g of NB dehydrated powder
(Oxoid) in 1 litre of distilled water and dispensing in the
required volumes either into bottles or conical flasks and
sterilized by autoclaving at 121°C for 15 min.
2.1.4 Brain Heart Infusion Broth (BHIB)
Dehydrated BHIB powder 37g (Oxoid ) was dissolved in 1 litre
of distilled water; dispensed in the required volumes into
bottles and sterilized by autoclaving at 121°C for 15 min.
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2.2 Isolates of P. multocida
The isolates of P. multocida used in this study were obtained
from veterinary investigation centres. Some strains from the
culture collection of Abdullahi (1987) identified and
characterized biochemically and serologically as P. multocida
type A were also used. All these strains were isolated from
cattle with a history of pneumonia or upper respiratory tract
infection.
2.2.1 Identification of Isolates of P.multocida
a) Biochemical tests using API 20E System
Isolates were identified as P. multocida based on their
biochemical characteristics using the API 20E system (API
Laboratory Products Ltd., Grafton Way, Basingstoke, Hants.).
A bacterial suspension prepared by emulsifying 3-4 isolated
colonies of P. multocida from DSA or BA in 1% horse serum in
distilled water was used to inoculate the tubes of the API 20E
strips. The biochemical tests were carried out according to the
manufacturer's instructions and the results were interpreted
using the API 20E index.
b) Staphylococcal hvaluronidase decapsulation test
In order to determine the capsular type of P. multocida
isolates the method by Carter and Rundell (1975) was followed.
Briefly, a colony of P. multocida from a DSA or BA plate was
streaked transversely across the whole plate of a freshly
prepared BA plate. A hyaluronidase producing strain of
Staphylococcus aureus was then streaked at right angles to the
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pasteurella streaks. The plate was placed in a moist container
and incubated at 37°C for 24 h. The hyaluronidase effect
manifested as a reduction in the size of the Pasteurella
colonies in the region adjacent to the staphylococcal streak,
indicating that those colonies of P. multocida belonged to
capsular type A.
2.2.2 Storage of Isolates of P.multocida
All the isolates were stored lyophilized and/or frozen at
-70°C. To store at -70°C, the cultures were grown in NB, NB
with 50% heat-inactivated filter-sterilized horse serum (HS) at
37°C for 6 h or in sheep blood overnight (o/n). Volumes (1ml)
were dispensed into plastic freezing vials (NUNC, Denmark) and
stored at -70°C.
2.3 Preparation of P. multocida antigens
2.3.1 Heat killed Organisms (HKO')
An iridescent colony from a DSA plate was inoculated into
10ml of NB and incubated at 37°C for 6 h on a multishaker. The
10ml broth culture was inoculated into 1 litre of NB and
incubated at 37°C for 18 h with continuous shaking. The cells
were harvested by centrifugation at 5000g for 20 min, washed
once in phosphate buffered saline (PBS: 0.137M NaCl, 0.003M KC1,
0.001M K^PO^ and 0.08M Na2HP0^, pH 7.4) and resuspended in 10ml
of PBS. The cells were checked for purity by plating onto a
blood agar plate and then killed by heating at 60°C for 90 min.
After heat treatment the cells were checked for viability by
streaking onto a BA plate and > • then lyophilized.
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2.3.2 Crude Capsular Antigen (CCA)
Preparation of crude capsular antigen was similar to that
described under the IHA test. The mucoid culture was washed off
a DSA plate with 3ml 0.01M PBS, pH 6.0 and 1.0ml of PBS pH 6.0,
containing 15 National Formulary Units of testicular
hyaluronidase (Sigma Chemical Co.) was added. The suspension was
placed in a water bath at 37°C for 3-4 h. It was then heated at
56°C for 30 min, after which the bacteria were removed by
centrifugation at 5,000g for 20 min. The supernatant consisting
of CCA was stored at -20°C in 0.5ml aliquots.
2.3.3 Lipopolvsaccharide (LPS')
a) Extraction of LPS by aqueous phenol
Lipopolys'accharides were extracted from dried cells of P.
multocida using the method originally described by Westphal et
al (1952) with certain modifications. NB (50ml) was inoculated
with a loopful of P. multocida (W674) from a BA plate and
incubated at 37°C for 6 h with shaking. This 50ml broth culture
was subsequently inoculated into 5 litres of NB and incubated at
37°C overnight with shaking. The cells were harvested by
centrifugation at 14000g for 20 min, washed once in distilled
water and resuspended in 50ml of distilled water. The cells
were checked for purity and then lyophilized.
Dried bacterial mass was resuspended to a concentration of 5%
w/v in distilled water and heated to 68°C in a water bath. An
equal volume of 90% w/v aqueous phenol was also heated to 68°C
and added to the prewarmed bacterial suspension mixed and
47
stirred at 68°C for 15 min. The mixture was transferred into
centrifuge tubes and cooled on ice for 10 min, to allow phase
separation to occur. The tubes were centrifuged at 8000g for 20
min, to complete phase separation. The upper aqueous phase,
containing the LPS, was carefully removed with a pasteur
pipette and the remaining suspension was retreated at 68°C with
the original volume of distilled water. Both upper aqueous
phases collected, were pooled and dialysed against running tap
water for 48 h to remove phenol. The dialysed liquid was
centrifuged at 10,000g for 20 min to remove the insoluble
deposit before being concentrated to 50% of its original volume
with a rotary evaporator. The concentrated solution was
centrifuged at 100,000g for 90 min, when LPS sedimented to form
a clear gelatinous pellet. The pellet was resuspended in
distilled water with the aid of a syringe fitted with a 23 gauge
needle and recentrifuged as above. The final pellet was
resuspended in 1ml of distilled water and lyophilized.
b) Preparation of LPS by Proteinase K enzyme digestion
Preparation of LPS in amounts suitable for analysis by PAGE
was essentially according to the method described by Hitchcock
and Brown (1983). P. multocLda was grown in 10ml NB at 37°C
overnight and the cells were washed once and resuspended in PBS
to an absorbance at 525nm of between 0.5 and 0.6. Cells from
1.5ml of bacterial suspension were sedimented in a
microcentrifuge at lOOOg for 3mins. The pellet was resuspended
in 50 jal of SDS-PAGE sample buffer (2% SDS, 4%
2-mercaptoethanol, 10% glycerol, 0.002% bromophenol blue in
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0.062M Tris-HCl buffer pH 6.8) and heated to 100°C for 10 min.
■t, Cooing
Proteinase K (25jag, Protease type XI, Sigma) in lOjul of sample
buffer was added, and this mixture incubated at 60°C for 60 min.
The resulting preparations were analysed by PAGE omitting SDS
from both stacking and separating gels.
2.3.4 Preparation of Outer Membranes COM-) by Sarkosvl Extraction
The OM were prepared according to the method described by
Shand et al (1985). A colony of P. multocida from a DSA plate
was inoculated into 30ml of NB and incubated at 37°C for 6 h
with shaking. Cells harvested from 30ml, were washed once in
PBS, resuspended in PBS and inoculated into 3 litres of either
NB, BHIB or any other specialized medium described in the
relevant chapter. An 18 h culture grown at 37°C with agitation
was harvested by centrifugation at 14,000g for 20 min, washed
twice in PBS and resuspended in 30ml distilled water. The cells
were disrupted by sonication for 3 bursts of 60s using 9mm probe
(MSE 150W Ultrasonic Disintegrator). The sonicated cell
suspension was centrifuged at 5,000g for 20 min, to sediment
the unbroken cells. The supernatant was collected and
centrifuged at 40,OOOg to pellet the cell envelopes. The
envelope pellet was washed twice and resuspended in 0.1M Tris
buffer, pH 7.4, to 8ml and extracted with 2ml of 10% Sarkosyl
v/v in distilled water (Sodium n-lauroyl sarcosinate 30% W/V
solution, Sigma Chemical Co.) for 30 min at 37°C. The insoluble
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OM was pelleted by centrifugation at 100,000g for 60 min,
washed once in 10ml Tris buffer (0.01M pH 7.4), resuspended in
lml of Tris buffer and stored at -20°C.
2.4 Inoculation of mice with P. multocida
2.4.1 Animals
Swiss white mice bred at MRI were used in these experiments,
unless otherwise stated. The mice were of either sex and 4-6
weeks old at the commencement of the experiments.
2.4.2 Determination of LD-q of P-multocida Isolates in Mice
Colonies of P. multocida from BA or DSA plates were
inoculated into 10ml of NB and incubated at 37°C for 6 h with
shaking. A series of ten-fold dilutions 10 ^ to 10 ^ of the NB
culture were made in peptone water and a viable count was
performed by the method of Miles and Misra (1938). Volumes (lml)
of each dilution were injected intraperitoneally into groups of
5 mice. The number of deaths per group was recorded up to 48 h
post-infection. The LD^q value was calculated by the method of
Karber (1939).
2.4.3 Vaccination and Challenge of Mice
a) Vaccines
Vaccines were prepared containing 5mg/ml of HKO. Lyophilized
cells were suspended to lOmg/ml in distilled water to which was
added an equal volume adjuvant (90% Bayol F (Esso), 10% Arlacel
(Sigma)) and the mixture homogenized until a stable emulsion was
formed.
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b) Vaccination of Mice
Mice were inoculated with 0.2ml of vaccine subcutaneously
(s.c.) under the loose skin of the groin on day 0. A booster
dose of 0.2ml of vaccine was given on day 14.
c) Challenge of Mice
IP
Mice were challenged^with 0.1ml of a live 6 h broth culture
of P. multocida on day 28. The challenge dose consisted of
either 10 LD,-q or a series of of P. multocida. An equal
number of unvaccinated (control) mice were also inoculated with
the same challenge dose in every experiment.
Blood was collected from the tail vein of each mouse before
being challenged. Blood was allowed to clot at room temperature
overnight. Serum was separated and stored at -20°C.
The number of deaths in each group of mice was recorded up to
48 h after challenge with live P. multocida. Surviving mice were
killed by placing them in a carbon dioxide chamber. Blood was
collected at post mortem from the inferior vena cava of each
mouse (using a 1ml syringe and 21 gauge needle). Pooled or
individual blood samples were allowed to clot overnight and
serum was separated and stored at -20°C.
2.5 Production of rabbit anti-P. multocida hyperimmune serum
Rabbits (lopear) of either sex between the ages of 4-6
months, bred at MRI, were used to raise serum against
P. multocida type A.
P.multocida was seeded heavily onto 2 BA plates in order to
obtain a confluent growth and incubated in a moist chamber at
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37°C overnight. The growth was harvested with 10ml of saline
using a bent sealed pasteur pipette to scrape gently the surface
of the agar. The bacteria were harvested by centrifugation and
resuspended in 10ml of saline.
Purity and viability tests of the cell suspension were
carried out as described previously. A viable count of the cell
suspension was performed by the method of Miles and Misra
(1938). The cell suspension was then diluted to 50ml with 0.3%
formal saline and incubated at 37°C overnight to kill the cells.
Following a sterility check a bacterial suspension containing
9
10 colony forming units (cfu)/ml was used to immunize rabbits.
Rabbits were bled from the ear vein and the serum tested for the
presence of antibodies to P. multocida by the IHA test.
Inoculations were carried out according to the schedule in
Table 2.1. Seven days after the final inoculation of formalin
killed organisms, 1.0ml of a live 6 h broth culture (washed once
in saline) was given intravenously (i.v.). A test bleed from
the marginal ear vein was carried out 7 days following the live
inoculation. Three days later the rabbits were bled by cardiac
puncture under terminal anaesthesia and blood allowed to clot at
room temperature overnight. Serum was separated and stored at
-20°C in 5ml aliquots.
2.6 Techniques
2.6.1 Indirect Haemagglutination Test (IHA)
The test was performed essantially according to the method
described by Carter (1955, 1972a) with certain modifications.
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Table 2.1. Immunization schedule for the production of
hyperimmune serum against P. multocida type A in
rabbits
Volume of killed cell Route of
Day suspension (10 cfu/ml) inoculation
1 1.0ml subcutaneous (s.c.)








Soluble capsular antigen extracted by hyaluronidase was used in
this test.
Confluent growth of P. multocida from a DSA plate was washed
off the plate with 3ml of 0.15M phosphate buffered saline (PBS)
at pH 6.0. To the bacterial suspension was added 1ml of PBS pH
6.0, containing 15 National Formulary Units of hyaluronidase
and incubated at 37°C for 4 h in a water bath. The bacterial
cells were then separated by centrifugation at 4,000g for 30
min. The supernate was transferred to another tube and 0.1ml of
packed sheep red blood cells (SRBC) fixed in 1% glutaraldehyde
(Sawada et al 1982) added. The suspension was incubated for a
further 2 h in a water bath at 37°C or overnight at 4°C (Carter
1984). The sensitized SRBC were removed by centrifugation at
l,000g for 5 min and washed 3 times with 10ml of saline. The
packed cells were then resuspended in 20ml of PBS to give a
final concentration of 0.5%. Doubling dilutions of test sera
were made in u-bottomed microtitre plates (Sterilin) using 50pil
of 0.3% formal saline as the diluent. Equal volumes (50jal) of
sensitized SRBC suspension were added to each well and the plate
shaken gently and incubated for 1-2 h at room temperature.
Sensitized cells were incubated with standard positive and
negative serum and unsensitized cells with test serum and
diluent as controls.
Coarse, agglutinated SRBC dispersed throughout the bottom of
the well, was interpreted as a positive reaction while
unagglutinated SRBC settling to the centre giving a
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characteristic button appearance was considered as a negative
reaction. The IHA titre was expressed as the reciprocal of the
highest dilution of serum indicating a positive reaction.
2.6.2 Enzyme-linked Immunosorbent Assay (ELISA)
I The method originally described b3<" Engval". and. Perlmanr.
(1972) was the basi~ of this assay. ELISA used in this study
was based on the method of Engvall and Perlmann (1972). P.
multocida whole cells were used as antigen. A confluent growth
of P. multocida from a DSA plate was removed in 3ml of saline.
The cells were harvested by centrifugation at 5,OOOg for 15 min
and washed once in 10ml of saline. These cells were resuspended
in 3ml of 0.5% formal saline, and diluted in 0.05M
Carbonate/bicarbonate buffer pH 9.6. Wells of microtitre plates
(type 129A, Dynatech Laboratories Ltd.) were coated with lOOyil
of antigen suspension by incubating overnight at 4°C and washed
3 times with PBS/Tween (PBS pH 7.4 containing 0.05% Tween 20).
The final wash was left on the plate for 3 min before it was
decanted. Samples were diluted in PBS/Tween and lOOyil volumes
were incubated in antigen coated wells for 3 h at 37°C. The
serum samples were decanted and the plate washed 3 times with
PBS/Tween. Volumes (lOO^il) of sheep anti-mouse IgG conjugated
with Horseradish peroxidase (Scottish Antibody Production Unit,
Lanarkshire, Scotland) (diluted 1 in 200 in PBS/Tween) were
added to each well and incubated for 1 h at 37°C. The plates
were washed 3 times in PBS/Tween. Finally lOOjal of fresh
substrate solution was added to each well. This consisted of
4mg of ortho-phenylenediamine (Sigma) and 4;al of ^1^02 per 10ml
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of 0.05M sodium phosphate - 0.024M citric acid buffer pH 5.0.
The reaction was terminated by adding 40jal of 2. 3M ^SO^/well
after 5 min. The optical densities of each well were read at
492nm on a Titertek Multiscan (Flow Laboratories, Irvine,
Ayrshire).
2.6.3 Sodium Dodecvl Sulphate Polvacrvlamide Gel
Electrophoresis (SDS-PAGE)
SDS-PAGE was employed to separate the OMP of P. multocida
based on their molecular weight and to analyze the LPS of P.
multocida. The procedure followed here was a modification of
the method of Laemmli (1970) described by Poxton and Brown
(1979). The details of the techniques were as follows:
2.6.3.1 Composition of buffers/reagents
Separating gel buffer,
0.75M Tris-HCl pH 8.8
0.2% SDS
Stacking gel buffer,
0.25M Tris-HCl pH 6 . 8
0.2% SDS
Acrylamide stock Solution (40%)








Sample buffer, (double strength)





2.6.3.2 Composition of polvacrvlamide gel
Acrylamide concentration in the separating gel was either 10%
or 14% as indicated in Table 2.2.
2.6.3.3 Procedure
Electrophoresis was performed at room temperature (20°C) on a
discontinuous vertical slab gel (170x140mm) prepared with the
aid of glass plate sandwich assembly, in an electrophoresis
apparatus (Raven Scientific Ltd., Haverhill, Suffolk, U.K.)
A 10% Separating gel was prepared by adding the accelerator
APS and the catalyst TEMED (NNN'N' tetramethylethylene diamine)
into the deaerated mixture of distilled water, separating gel
buffer and acrylamide (Table 2.2). The gel was poured slowly
between glass plates using a glass pipette and overlaid with
water saturated butan-2-ol and allowed to polymerise for 30 min.
The water-saturated butanol was removed from the surface of
the polymerised separating gel and the stacking gel (Table 2.2)
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Table 2.2. Composition of Polyacrylamide gels.




Distilled water 6 . 95 3..45 3..50
Separating gel buffer 17.,50 17,.50
Stacking gel buffer 5,.00
Acrylamide stock solution (40%) 8..75 12,.25 1,.00
TEMED 0..05 0 .05 0 .02
Ammonium persulphate (15mg/ml) 1 .75 1 .75 0 .50
(APS)
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mixture prepared in a similar manner to the separating gel
poured on top. A suitable comb was inserted initially at an
angle to exclude air bubbles, and the gel allowed to
polymerise.
Samples were prepared for electrophoresis by heating equal
volumes of sample and double strength sample buffer at 100°C for
3 min. Samples were applied to the wells filled with electrode
buffer and electrophoresis was carried out first at 60V until
the samples had entered the separating gel, and subsequently at
150V until the dye front had reached 7.5cm from the top of the
separating gel.
LPS was analysed on 14% polyacrylamide gels, omitting SDS
from both the stacking and separating gel buffers. The gels
were stained for proteins with Coomassie brilliant-blue
(sequential staining method) and with Silver Stain for LPS by
the methods described by Hancock and Poxton (1988) .
2.6.4 Western Blotting
Comparison of serological responses of mice to different
vaccines of P. multocida and characterisation of monoclonal
antibodies were carried out by the "Western Blotting" technique,
first described by Towbin et al (1979). Proteins or LPS
separated on PAGE were electrophoretically transferred to
nitrocellulose (NC) membrane (Schleicher and Schuell, GMBH,
D-3354 Dassel, West Germany) in transfer buffer (0.025M Tris,
0.2M glycine and 25% aqueous methanol, pH 8.3) at 40mA for 16 h
in an immunoblot apparatus. In order to ascertain transfer had
taken place, NC membrane was stained with 0.2% Ponceau S (Sigma)
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in distilled water for 10 min. and molecular mass markers
marked on blot, then rinsed in water and cleared. The membrane
was washed for 10 min in Tris-buffered saline (TBS) (20mM Tris,
500mM NaCl, pH 7.5) and placed in 3% w/v gelatin in TBS for 45
min to block free binding sites. After blocking with gelatin, NC
membrane was probed with primary antibody (polyclonal serum,
ascitic fluid 1 in 100 in PBS or undiluted monoclonal culture
supernatant) for 1 h at room temperature with shaking. This was
followed by rinsing the membrane in distilled water and washing
twice (10 min for each wash) in TBS containing 0.25% Tween
(TTBS). In order to detect bound antibody, the membrane was
incubated with sheep anti-mouse IgG - horse radish peroxidase
conjugate (Scottish Antibody Production Unit, Lanarkshire,
Scotland) diluted 1 in 200 in TTBS for 1 h at room temperature
with shaking and subsequently washed twice for 10 min in TTBS.
The nitrocellulose membrane was then incubated with freshly
prepared substrate solution (30mg 4-chloro-1-napthol, 10ml
methanol, 30 ;al ^2^2 TBS) until dark blue bands appeared
(approximately 10 min). The reaction was terminated by washing
in excess distilled water.
2.7 Media and Medium Constituents Used for Monoclonal
Antibody Production
2.7.1 Basic medium
Basic medium was prepared by adding the following constituents
into 500 ml of sterile RPMI 1640 (Flow Laboratories Cat. No.
10-601-22).
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12.5 ml 8% NaHC03 (BDH)
10.0 ml 0.5M Hepes (Sigma)
5.0 ml 0.1M Glutamine (Sigma)
4.0 ml 0.1M Na-Pyruvate (Gibco)
2.7.2 Fetal Calf Serum
Heat inactivated fetal calf serum (FCS-Gibco) was added into 500
ml basic medium in 50 ml, 75 ml and 100 ml volumes to obtain 10%,
15% and 20% FCS respectively.
2.7.3 HT and HAT media
HT and HAT media were made up, at least one week prior to use by
adding 4 ml of the required 50 x stock solution (Gibco) into 200 ml
of 20% FCS, and frozen pending sterility checks.
2.7.4 Sterility check
Basic medium, FCS, HT and HAT media were checked for sterility
by adding 1 volume of the medium into 1 volume of nutrient broth in
a sterile universal and incubating one week at 37°C and at room
temperature.
2.7.5 Mixed Thymocyte Medium (MTM)
The method described by Reading (1982) was followed to prepare
MTM. Two rats of different strains (e.g. Wistar, August) at 5-6
weeks of age were used. Their thymuses were removed aseptically
and homogenized in basic medium to make a cell suspension. The
cells were washed 3 times with basic medium and resuspended in 15%
FCS medium and cultured at a cell density of 5.0 x 10^ cells/ml for
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36-48 h only. The medium was harvested by removing cells and
debris by centrifugation at 4000g for 10 mins. Supernatants were
dispensed into 10 ml volumes and stored at -20°C until used.
2.7.6 Polyethylene Glycol (PEG)
Polyethylene glycol (50%) was prepared by autoclaving 5g of
crystalline PEG 4000 (BDH). The sterile molten PEG was allowed to
cool to 37°C and then 5 ml of serum free RPMI at 37°C was added.
The mixture was aliquoted in 1.2 ml volumes and stored in the dark
at 4°C. Immediately prior to fusion PEG was warmed to 37°C and pH
adjusted to between 8.5 and 9.0 with sterile 2M Tris/HCl.
2.7.7 Freezing Medium
Freezing medium was prepared by mixing 90% FCS with 10% fresh
dimethyl sulphoxide (DMSO - Sigma) and kept frozen at -20°C until
used.
2.7.8 Versene (EDTA in PBS) Stripping Solution
A 10 mM solution of EDTA (Sigma) was prepared in PBS into which
1% phenol red was added and the pH adjusted to between 7.1 and 7.3.
The solution was sterilized through membrane filters (0.2 jam) and
dispensed in 15 ml volumes.
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CHAPTER 3
Expression of Outer Membrane Proteins by Pasteurella multocida
Grown In vivo and in vitro Under Iron Restricted Conditions.
INTRODUCTION
SDS-PAGE analysis of the outer membrane proteins (OMPs) of P.
multocida isolated from rabbits, turkeys, pigs and cattle grown in
complex laboratory media and the recognition of certain major OMPs
by immune sera has been reviewed in the general introduction.
Expression of iron-regulated proteins (IRP) by some
Gram-negative bacteria and their possible role in the host immunity
was also discussed.
In most studies iron restriction in vitro has been achieved by
addition of the iron chelator 2,2'-dipyridyl into BHIB or NB
(Griffiths et al 1985, Snipes et al 1988, Ikeda and Hirsh 1988,
Donachie and Gilmour 1988).
The expression of IRPs with molecular masses of 96, 84 and 80
kDa by P. multocida of turkey origin grown in in vitro in turkey
plasma and in iron-depleted BHIB was reported by Snipes et al
(1988). When all sixteen serotypes of P. multocida (Heddleston's)
were grown in vitro under iron restricted conditions an
antigenically related IRP of molecular mass 84 kDa was produced
(Ikeda and Hirsh 1988).
P. haemolytica, a closely related species to P. multocida was
shown to produce several high molecular mass OMPs when grown in
vivo and in vitro under iron restriction conditions (Donachie and
Gilmour 1988). Recognition of the IRPs by antibodies present in
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sera and lung washes of lambs recovering from pneumonic
pasteurellosis, indicated the importance of incorporating these
antigens in the development of new vaccines.
The experiments described here were, therefore, designed to
study the OMP profile of P. mulCocida type A of bovine origin
grown in vivo and in vitro under iron restricted conditions.
RESULTS
3.1 Growth of P. multocida in vivo
3.1.1 Growth in chambers implanted intraoeritoneallv in mice.
An attempt was made to grow P. multocida in silicon chambers
[1.0 cm long silicon tubes sealed with 6 mm diameter, 0.45 pun
filter membranes (Millipore, UK), on either end] implanted in the
g
peritoneal cavity in mice. The cells recovered were 3.0 x 10 cfu
in total from 20 chambers implanted intraperitoneally in 10 mice
after an incubation period of 30 days with an initial bacterial
9
count of 3.0 x 10 per chamber. As this number of bacteria was
insufficient for the preparation of OMPs or vaccines the method was
discontinued.
3.1.2 Growth in ascitic fluid of tumour induced mice
In order to obtain in vivo cells, P. multocida was grown in
ascitic fluid of tumour induced mice. Tumour growth was promoted
by inoculating plasmacytoma cells into mice which had been treated
with 0.5 ml of pristane (2,6,10,14-tetramethylpentadecane - Sigma)
g
three days previously. P. multocida 4.0 x 10 cfu in 0.5 ml of
PBS were inoculated into ascitic fluid. The bacteria harvested
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after 24h from 2 ml of ascitic fluid collected from six mice were
5.5 x 107 cfu and were insufficient to fulfill the above stated
criterion.
3.1.3 Recovery of P. multocida from pleural effusion of sheep.
As an alternative method for the recovery of in vivo P.
multocida cells, lambs were inoculated intrapleurally with 5.0 ml
9
of a 6h broth culture (1.5 x 10 cfu/ml) between the 7th and 8th
left ribs using a 19 gauge needle fitted onto a 5 ml syringe. Of
the three lambs infected one was found dead 18-22h following
inoculation. The other two lambs which survived were killed by
anaesthesia with intravenous pentobarbitone and exsanguination.
Pleural effusion (up to 300 ml/sheep) was collected into two
sterile bottles containing 2 ml of 100 juM EDTA which prevented the
formation of fibrin clots. After removal of large particles by
coarse filtration through muslin the filtrate was centrifuged at
lOOOg for 15 min to deposit blood cells, cell debris and other host
cells. Bacterial cells were then pelleted from the supernatant by
centrifugation at 5000g for 20 min, washed 3 times in PBS before
being resuspended in 10 ml of PBS. Cells in the suspension were
counted by the dilution method of Miles and Misra (1938) , and
checked for purity by examining a smear stained with Giemsa-stain
g
and by plating onto SBA. An average of 1.25 x 10 cfu/ml
bacteria were present in the pleural fluid of the two lambs. Half
of the cell suspension was used to prepare OMP by the method
described in section 2.3.4 while the remainder was heat inactivated
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and freeze-dried (section 2.3.1) in preparation for use as a
vaccine.
3.2 Growth of P. multocida in vitro under iron restricted
and iron replete conditions
For this study P. multocida were grown in the following media.
3.2.1 BHIB or NB
P. multocida strains were grown in either BHIB or NB for
18 h at 37°C and 40°C.
3.2.2 80% Horse serum
P. multocida was also grown in 80% horse serum (Gibco) with 20%
PBS for 18h at 37°C as described by Donachie and Gilmour (1988) .
3.2.3 BHIB depleted of iron
Bacteria were grown in 100 ml BHIB containing 2,2'-dipyridyl
(BHIB 2,2'-dp) at 150 and 200 ^, at 37°C and 40°C for 18 h to
optimise the concentration of 2,2'-dipyridyl and the growth
temperature. Cells harvested by centrifugation at 5000g for 20 min
were washed once in PBS before being resuspended in 2 ml distilled
water. Samples (40 jul) were analysed by SDS-PAGE.
Determination of optimum concentration of 2.2'-dipyridvl and
growth temperature by SDS-PAGE of whole cell preparations of P.
multocida (A26)
Fig. 3.1 shows P. multocida whole cells separated on SDS-PAGE
Fig. 3.1. SDS-PAGE analysis of F. multocida (A26)
whole cells. (Lane 1) Standards with
molecular masses indicated in kDa; (Lane 2)
whole cells grown in BHIB at 37°C; (Lane 3)
BHIB 2,2'-dipyridyl (150 jjM) at 37°C; (Lane
4) BHIB 2,2'-dipyridyl (200 juM) at 37°C;
(Lane 5) BHIB at 40°C; (Lane 6) BHIB
2,2'-dipyridyl (150 juM) at 40°C; (Lane 7) BHIB
2,2'-dipyridyl (200 juM) at 40°C.
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and stained with Coomasie blue. The major proteins with molecular
masses of 25.0, 39.0, 47.0, 60.0, 77.0 and 97.0 kDa were present
in all preparations. A high molecular mass protein of 84 kDa was
present in whole cells grown in BHIB containing 2,2'-dipyridyl at
37°C and 40°C, but absent from those grown in BHIB, and was
considered to be an iron-regulated OMP. This protein was expressed
best in cultures containing 150 ^iM dipyridyl and grown at 37°C
(Fig. 3.1, lane 3). These conditions were, therefore, adopted
as the standard procedure.
Samples were analysed on 10% polyacrylamide gels and stained
with Coomassie blue by the sequential staining method described by
Hancock and Poxton (1988) .
3.3 Analysis of OMP preparations of five isolates by SDS-PAGE
Five isolates of P. multocida (Strain 10322, W674, X200, W829,
X120) selected randomly were grown in NB, NB containing
2,2'-dipyridyl and 80% horse serum. The OMPs prepared (see Section
2.3.4) were analysed by SDS-PAGE and the protein profile was
compared.
Fig. 3.2 shows the results of SDS PAGE analysis of outer
membrane preparations of 5 different isolates of P. multocida
(Strain 10322, W674, X200, W829 and X120) grown in NB, 80% horse
serum and NB containing 2,2'-dipyridyl. The high molecular mass OMP
of 84 kDa observed previously in whole cell preparations (Fig.
3.1) was also present in the outer membrane preparations of all 5
isolates grown in NB containing 2,2'-dipyridyl, but was absent in
those from horse serum and NB cultures. One other high molecular
Fig. 3.2. OM preparations of five isolates of P.
multocida grown under different cultural
conditions and separated on SDS-PAGE.
Position of standards with molecular masses
indicated in kDa; (Lane 1) W674 in NB; (Lane
2) W674 in horse serum; (Lane 3) W674 in NB
2,2'-dipyridyl; (Lane 4) reference 10322 in
NB; (Lane 5) reference 10322 in horse serum;
(Lane 6) reference 10322 in NB 2,2'-dipyridyl;
(Lane 7) X200 in NB; (Lane 8) X200 in horse
serum; (Lane 9) X200 in NB
2,2'-dipyridyl;(Lane 10) W829 in NB; (Lane
11) W829 in horse serum; (Lane 12) W829 in NB
2,2'-dipyridyl; (Lane 13) X120 in NB; (Lane





mass protein of 87 kDa was evident in outer membrane preparations
of dipyridyl grown cultures and in all except one (strain 10322) of
horse serum grown cultures.
Variations in the OMP profile between isolates were observed
when they were grown in horse serum. Two isolates (strain 10322
and W674) produced OMPs of 91 and 92.5 respectively, while in W829
and X120 a protein with molecular mass of 89 kDa was observed in
horse serum grown cultures.
Major OMPs of 77 and those below 47 kDa were observed to be
common to all isolates.
3.4 Comparison of outer membrane profile of P. multocida (A26)
grown in vitro and in vivo
This strain was selected because of its low for use in
immunization and challenge experiments (described in Chapter 4).
The protein expression of Strain A26 of P. multocida grown in
vivo was compared with cells grown in vitro under iron restriction
conditions as described in 3.3.
Fig. 3.3 shows the outer membrane protein profile of P.
multocida (A26) grown in vivo and in vitro under various
conditions. The protein profile observed here was very similar to
fia-
that described previously with another five type A strains (j3.2).
The strain A26 when grown in vivo also expressed the 84 and 87 kDa
proteins which were produced under iron-restricted conditions in
vitro. Additionally, two other proteins with molecular masses of
36 and 22 kDa were observed to be unique to cells grown in vivo
(Fig. 3.3).
Fig. 3.3. SDS- PAGE of OMPs of P. multocida
(A26), position of molecular mass standards;
(Lane 1) grown in NB; (Lane 2) in horse serum;






As iron restriction occurs naturally in an infection in the
host, some bacteria adapt to this environment by producing
siderophores and high molecular mass OMPs (Griffiths 1985;
Overbeeke and Lugtenberg 1980). Production of siderophores by P.
multocida has been reported by Hu et al (1986) . The changes that
may occur in the protein composition of the outer membrane of P.
multocida when grown in vitro under iron restriction and in vivo
are yet to be understood.
These experiments were designed to compare the expression of
OMPs by P. multocida grown in vitro under iron restriction and in
vivo, with that grown in iron rich medium.
The major OMPs observed in in vitro cultures in iron replete
medium in this study were those with molecular masses of 21 or 25,
32, 33, 47 and 77 kDa as compared to those of 27, 37.5, 49.5,
58.7 and 64.4 kDa described by Lu et al (1988a). The heavy band in
a doublet with an approximate molecular mass of 36 kDa observed by
Lugtenberg et al (1986) was also evident in this study but with a
slightly lower molecular mass of 33 kDa. Corbett et al (1984)
described a matrix protein of 35 kDa found in an outer membrane
preparation, KSCN extract and 2.5% NaCl extract and also in the
ribosomal fraction of P. multocida. The differences in molecular
masses of major proteins may have arisen due to the fact that they
were not electrophoresed under identical conditions. The protein
being referred to as 37.5, 36, 35 and 33 kDa, are very likely to be
the same major OMP.
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Cells of P. multocida grown under iron-depleted conditions
expressed proteins of high molecular mass which were not present
when the same culture was grown in NB or BHIB. These proteins were
87 and 84 kDa in molecular mass and were also found in cells
recovered directly without subculture from the pleural fluid of
lambs with experimentally induced pleural effusions. Only the 87
kDa protein was evident when bacteria were grown in horse serum
(80%). In addition to 87 and 84 kDa proteins, two other proteins
of 36 and 22 kDa were evident in in vivo grown cells.
Expression of a protein of 84 kDa by all the somatic types of P.
multocida (except serotype 12) occurred when bacteria were grown in
BHIB containing 2,2'-dipyridyl (Ikeda and Hirsh 1988). This is in
agreement with the present findings, in that all six isolates
examined have produced 84 kDa protein under iron restriction. When
grown in turkey plasma at 41°C, P. multocida of turkey origin
expressed OMPs with molecular masses of 96, 84 and 80 kDa, which
were also induced when the same strain was grown in BHIB with
2,2'-dipyridyl (Snipes et al 1988).
In this present study, the protein with 96 kDa molecular mass
was not observed, but an 87 kDa protein was observed. Here P.
multocida (A26) grown in NB with 2,2'-dipyridyl expressed an
iron-regulated protein with molecular mass of 80 kDa. The
differences seen in proteins expressed by P. multocida in this
study may be due to the fact that the strains studied were bovine
isolates which may produce different OMPs under iron restriction,
compared to turkey isolates.
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Although the role of these high molecular mass OMPs of P.
multocida is not known, the involvement of similar proteins of
other Gram-negative bacteria in iron acquisition is well documented
(Sokol and Wood 1983; Griffiths 1985). Demonstration of antibodies
to the iron-regulated proteins of other Gram-negative bacteria
(Shand et al 1985; Griffiths et al; Bolin et al 1987; Donachie and
Gilmour 1988) and the protective capacity of such antibodies (Bolin
et al 1987) indicates the possible use of these proteins as
candidate antigens in the formulation of new vaccines. Evaluation
of the protective efficacy of vaccines containing P. multocida
grown under different cultural conditions described in this study
will be discussed in the next chapter.
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CHAPTER 4
Evaluation of the Immune Response of Mice to P. multocida Grown
in vivo and in vitro Under Iron Restricted Conditions
INTRODUCTION
The outer membrane protein (OMP) profile of P. multocida grown
under various conditions was discussed in the previous chapter.
The immunogenicity of heat killed P. multocida whole cells of
bovine origin grown in iron replete medium, was studied in mice by
Abdullahi (1987). Although antibodies to major OMPs were
demonstrated in immune sera from mice, they were not related to the
protection induced by P. multocida whole cell vaccines. The
presence of an immunogenic OMP of 37.5 kDa expressed on the cell
surface of P. multocida isolates from rabbits indicated its
possible importance in immunity in rabbits (Lu et al 1988a and
1988b) .
Since it is evident that P. multocida produce additional OMPs
under iron restriction, the role of these proteins in the immune
response of mice is an important aspect which needs to be
investigated. Active immunization of mice with vaccines
incorporating cells grown in vivo and in vitro under iron
restriction and evaluation of the immune response of mice to these
cells was therefore studied.
RESULTS
4.1. Selection of an isolate for vaccine experiments
Most bovine isolates of P. multocida type A were not very
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7 8virulent for mice with LD5Q being in the order of 10 -10 live
organisms (Abdullahi 1987) . In order to evaluate the immune
response of P. multocida grown in vitro and in vivo in mice, a
highly virulent strain was required. The virulence of four
strains, in terms of LD,-q, was assessed after two passages in mice.
4.1.1. Passage of P. multocida in mice
A six hour broth culture of each isolate (A33, A580, X109 and
A26) was inoculated intraperitoneally in 0.2 ml volumes into
individual mice. Blood (0.1 ml) collected via the inferior vena
cava of dead mice was subsequently inoculated intraperitoneally
into other mice. Heart blood for the second set of mice was plated
onto SBA, and incubated at 37°C in a moist chamber. The cultures
grown on SBA were used to assess the .
4.1.2. Determination of the LD-q of passaged cultures.
Table 4.1 indicates the LD,_q values of passaged cultures
assessed by the method described in section 2.4.2.
Strain A26 demonstrated the highest virulence (an of 6
organisms) and was selected to be used in the vaccine experiment.
4.2. Determination of virulence (LP..^) of strain A26 grown
under various conditions
P. multocida when grown under various conditions expressed
different outer membrane proteins. The effect of these proteins on
the virulence of the organism was studied in order to determine
whether virulence could be correlated with the ability of these
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Table 4.1. ^50 titrati°n °f mouse passaged cultures
LD^q in terms of
Strain Colony counts of 6h titre No. of
No. broth cultures (cfu/ml) organisms
X109 3.5 x 109 10"8-69 7
9 -8 5
A26 2.0 x 10 10 6
9 -7 39
A580 2.5 x 10 10 102
A33 5.0 x 107 10"3,37 2 x 104
77
proteins to elicit an antibody response. A ^50 study of P.
multocida (A26) grown in vitro and in vivo was therefore performed.
Ten-fold serial dilutions in peptone water were made from cultures
of bacteria grown in NB, NB containing 2,2'-dipyridyl and 80% horse
serum for 6h at 37°C. In vivo grown P. multocida, recovered from
pleural fluid of lambs, were also diluted in a similar manner and
the LD,-q was determined as described in section 2.4.2. The number
of viable bacteria in cell suspensions were counted by the method
of Miles and Misra (1938). Table 4.2 indicates the values of
cells grown under various conditions.
As indicated in the table 4.2, cells grown in NB and in vivo
demonstrated the greatest virulence, while NB containing
2,2'-dipyridyl and horse serum grown cells were found to be the
least virulent.
4.3. Immunisation of mice with bacteria grown in vitro under
iron restricted conditions, and in vivo.
a) Bacterial strain
P. multocida A26 strain was used in this study.
b) Preparation of vaccines
Four vaccines each incorporating cells grown in either NB,
horse serum and NB with 2,2'-dipyridyl grown, or in vivo cells


































































































As described in section 2.4.1.
d) Immunization protocol
Each vaccine (0.2 ml) containing heat killed organism in
adjuvant was inoculated subcutaneously into seventy-two mice on day
0 and day 14. An equal number of mice were allocated as
unvaccinated controls.
4.3.1. Challenge of mice
a) Preparation of challenge inocula
The homologous strain (A26) was passaged twice in mice and used
to prepare the challenge inocula. Two to three colonies from the
passaged culture, from SBA plates, were inoculated into 10 ml of
NB and grown at 37°C for 6h with constant agitation. A series of
doubling dilutions of the bacterial suspension (up to 27th
dilution) was made in NB. The number of viable bacteria in the
suspension was counted by the dilution method of Miles and Misra
9
(1938) and was found to be 8.5 x 10 cfu/ml.
b) Inoculation of mice
Three mice from each of the vaccinated and unvaccinated control
groups were challenged intraperitoneally with 0.1 ml of varying
-4 -27
doubling dilutions ranging from the 2 to the 2 , on day 28.
Deaths were recorded for up to 48 h after challenge (Table 4.3).
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4.3.2. Evaluation of the immune response of mice to vaccines
incorporating heat killed organisms grown under various conditions.
The response of mice to each vaccine was measured by the means
of the log protection and serological analysis.
a) Determination of LD^ and log protection afforded by each
vaccine.
The for each group of mice was calculated by the method of
Karber (1939). The log protection for each vaccine was expressed
as follows:
Log protection obtained by the vaccine =
value for the - ^50 va^ue f°r the
control mice vaccinated mice
Table 4.3 documents the results obtained.
The vaccine containing whole cells grown in NB with
2,2'-dipyridyl produced the highest log protection (> 6.36), of the
four vaccines tested in mice. The lowest protection (5.07) was
afforded by the in vivo cell vaccine. Although this was the case,
the differences between the log protections afforded by four
vaccines were small, and not statistically significant.
The of the strain A26 in this experiment was found to be
330 organisms when compared to the earlier value of 6.
This experiment was repeated with a higher challenge. Each
vaccine was inoculated into forty-five mice, according to the
























































































































































































undiluted to 2 (1 in 256) of a doubling dilution series. Five
mice from each group of vaccinated and unvaccinated controls were
challenged with these dilutions; and observed for 48h. The 6h
broth culture used for challenging mice contained 1.2 x 10^
cfu/ml.
One mouse each from the groups vaccinated with NB and NB
containing 2,2'-dipyridyl grown cells survived the highest dilution
- 8
(2 ) of the challenge. All the other mice died following
challenge. Therefore, no evaluation of the vaccines could be made.
b) Serology
(i) Sera
Prior to infection a pooled sample of serum from each group of
mice was prepared as described in section 2.4.3 (c) and labelled as
"pre-challenge sera". Surviving mice in each of the vaccinated and
unvaccinated groups were killed 48h after infection by cervical
dislocation and blood collected from the inferior vena cava. Serum
was separated and stored at -20°C until analysis.
(ii) Indirect ELISA to detect the antibody response of mice
immunized with P. multocida whole cells grown under various
conditions.
Whole cell ELISA was carried out basically according to the
method described in section 2.6.2 with a modification of the
preparation of whole cell antigen in coating plates. P. multocida
grown in 10 ml NB, 80% horse serum bv NB containing 2,2'-dipyridyl
for 6h at 37°C were washed once in PBS and resuspended to the same
Fig. 4.1. Antibody response of mice immunized with cells
grown in NB ( ) , horse serum ( ) , NB
containing 2,2'-dipyridyl ( ) and in vivo
( -e- ) against NB grown P. mulCocida (A26)
cells determined by indirect ELISA. The
line indicates the response of the
unvaccinated control mice.
Fig. 4.2. Antibody response of mice immunized with cells
grown in NB ( -*-) , horse serum ( ) , NB
containing 2,2'-dipyridyl ( ) and in vivo
( -e~ ) against horse serum grown P. multocida
(A26) cells determined by indirect ELISA. The










Fig.4.1 Reactivity of mouse serum against nutrient broth
grown P.multocida cells determined by Indirect ELISA
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Serum Dilution (Log Scale)
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Fig.4.2 Reactivity of mouse s
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Fig. 4.3. Antibody response of mice immunized with cells
grown in NB ( ) , horse serum () , NB
containing 2,2'-dipyridyl ( ) and in vivo
( -B- ) against NB 2,2'-dipyridyl grown P.
multocida (A26) cells determined by indirect
ELISA. The line indicates the response
of the unvaccinated control mice.
Fig. 4.4. Antibody response of mice immunized with cells
grown in NB ( ) , horse serum ( ) , NB
containing 2,2'-dipyridyl ( ) and in vivo
( -a- ) against in vivo grown P. multocida
(A26) cells determined by indirect ELISA. The
line indicates the response of the
unvaccinated control mice.
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Fig.4.3 Reactivity of mouse serum against NB containing
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Fig.4.4 Reactiuity of mouse serum against in vivo grown
P.multocida cells determined by Indirect ELISA
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volume in carbonate/bicarbonate buffer. Cells grown in vivo were
also adjusted to the same concentration in carbonate/bicarbonate
buffer after being washed once in PBS. In order to optimise the
antigen and antibody concentration, a checkerboard titration was
carried out with NB grown cells as antigen and mouse immune serum
from chamber implanted mice as the standard positive (see appendix
1.1 for results). Each bacterial suspension (NB, horse serum, NB
containing 2,2'-dipyridyl and in vivo grown) was coated onto a
separate microtitre plate at the optimum concentration of antigen
107 cfu/ml, 100 jal/well.
After an initial dilution of 1 in 50, doubling dilutions (up to
2 ^) of sera (pre - challenge and post- challenge) from the four
vaccinated groups and the unvaccinated control mice were made in
PBS. These sera were tested against all four antigens by ELISA as
described in section 2.6.2.
Fig. 4.1, 4.2, 4.3 and 4.4 show the ELISA results of
pre-challenge immune response of mice to different whole cell
antigens.
The antibody response induced by the vaccine consisting of NB
2,2'-dipyridyl grown cells was greater when compared to that
induced by cells grown in NB, and in vivo (Fig. 4.1, 4.3 and
4.4). Serum of mice immunized with horse serum grown cells
demonstrated the highest response only against the homologous cells
and the lowest response against the cells grown under other
conditions (Fig. 4.2). The response induced by the in vivo grown




Western blots of NB 2,2'-dipyridyl grown whole cells and OMP
preparations of the strain A26 were prepared as in sections 2.6.3
and 2.6.4 and probed with sera (pre and post-challenge) at a 1 in
50 dilution. Antigen was transferred onto nitrocellulose paper,
cut into strips and then probed with serum.
Fig. 4.5 and 4.6 demonstrate the reactivity of sera of
vaccinated and unvaccinated control mice against separated OMP and
whole cells of strain A26 respectively in Western blots. No
antibodies were directed against the 84 and 87 kDa iron regulated
proteins in sera of mice immunized with bacteria expressing these
proteins (Lanes 3, 4, 8, 9 in Fig. 4.5). However, antibodies in
sera of mice vaccinated with NB, NB containing 2,2dipyridyl grown
cells reacted with 25, 33, 60, 77 and 97 kDa outer membrane
proteins (Lanes 1, 3, 6 and 8 in Figs. 4.5, 4.6). Sera of mice
immunized with horse serum grown cells recognised only the 25 and
33 kDa proteins. Sera from mice vaccinated with in vivo cells
recognised proteins of molecular mass 25, 33 and 77 kDa.
DISCUSSION
The object of the experiments described was to study the
importance of iron-regulated proteins expressed by P. multocida in
the induction of immunity in mice.
For the purpose of challenging mice immunized with different
vaccines, a strain with high virulence (low LD^q) was required as
most of the strains of P. multocida type A were less virulent than
Fig. 4.5. Western blots of OMP of P. multocida (A26)
grown in NB containing 2,2'-dipyridyl probed
with sera of mice vaccinated with cells in 1 -
NB, 2 - horse serum, 3 - NB 2,2'-dipyridyl, 4
in vivo before challenge; 6-9 as above






Fig. 4.6. Western blots of P. multocida (A26) whole
cells grown in NB containing 2,2'-dipyridyl,
probed with serum of mice vaccinated with
cells grown in 1 - NB, 2 - horse serum, 3 - NB
2,2'-dipyridyl, 4 - in vivo before challenge;






other serotypes for mice (Carter and Bigland 1958; Abdullahi 1987).
After passage of four strains of P. multocida through mice to
enhance their virulence, a strain with a low LD^q (6 organisms) was
selected. However, the virulence of this strain changed in every
experiment and affected the reproducibility of the experimental
results. The use of a strain with stability in virulence is an
essential criterion in vaccine experiments.
In mouse immunization experiments, although protection was
demonstrated by each vaccine on challenge a highly immunogenic
vaccine, determined serologically, could not be identified. It is
known that protection in mice can be achieved by immunization with
whole cells of P. multocida (Collins 1973; Abdullahi 1987). The
experiments described here, were planned in order to study the
differences between the vaccines consisting of whole cells grown
under various conditions for their protective ability. Due to the
low number of mice used in the challenge in this experiment as a
result of advice from a statistician, the protection afforded by
each vaccine could not be statistically analysed. However, there
was a suggestion that the vaccine comprising of cells grown in NB
containing 2,2'-dipyridyl induced a greater protection than the
others.
The antibody response of mice immunized with cells grown in NB
containing 2,2'-dipyridyl was found to be greater than that of mice
immunized with cells grown under other conditions , as determined by
ELISA. Growth of P. multocida under iron restricted conditions in
vitro may have produced other changes in antigenic profile than
just the expression of iron regulated proteins on the bacterial
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surface to which the mice responded. This view is supported by the
appearance of two additional low molecular mass proteins recognised
by sera from mice immunized with cells grown in NB containing
2,2'-dipyridyl, in Western blots (Fig. 4.6 - lane 3).
The high antibody response observed by ELISA against homologous
cells in the sera of mice immunized with bacteria grown in horse
serum suggests that these cells expressed different surface
antigens than the cells grown in other ways. This was confirmed by
the results of Western blots, where the least number of proteins
of the dipyridyl grown cells were recognised by sera from mice
immunized with cells grown in horse serum.
The failure to demonstrate antibodies to iron regulated proteins
of 84 and 87 kDa may be because these proteins were not immunogenic
in mice or they may not be exposed on the cell surface. The strong
antibody response directed against a 37.5 kDa OMP observed in
immune rabbit serum by Lu et al (1988a and 1988b) suggested that
this protein was expressed on the cell surface and was easily
accessible to the rabbit immune system. A similar response to the
33 kDa OMP in sera of all vaccinated mice, irrespective of the
growth conditions, was demonstrated in this study. It is clear
that these two proteins are probably the same antigen.
fVom the position of thUse proteins in the gels and immunoblots,
they appear to be the same antigen. However, the differences in
the molecular mass may have arisen as they were not electrophoresed
under identical conditions.
Cells grown in NB and in vivo demonstrated the highest
virulence. One could therefore, propose that cell surface
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antigens or factors responsible for virulence could confer on these
cells a greater imraunogenicity. In this study no such relation
between virulence and immunogenicity was established.
The results of these experiments have characterized some iron
regulated proteins expressed by P. multocida. Although no
response to these proteins was observed in mice, it will be
important to investigate their role in immunity in cattle which may
respond to these proteins differently.
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CHAPTER 5
Effector Mechanisms of Immunity to P. multocida in Mice
INTRODUCTION
As has been previously discussed in Chapter 1, the mechanisms
of immunity to P. multocida still remain unresolved. Resistance
of type A P. multocida to phagocytosis (Maheswaran and Thies 1979;
Rush et al 1981; Ryu et al 1984) and to serum killing, particularly
of the clinical isolates of type A (Blau et al 1987) have been
reported.
Rises in titres of bactericidal antibodies in mice by
vaccinating with KSCN extract of P. multocida was shown by Mukkur
(1980). However, the mechanism or mechanisms by which the
vaccinated animals resist challenge and thereby survive has yet to
be elucidated.
The objectives of this study were, therefore, to investigate
the susceptibility of P. multocida type A to killing by serum, and
to phagocytosis by mouse peritoneal macrophages, and the ability of
protective vaccines to stimulate these mechanisms of immunity in
mice.
RESULTS
P. multocida strain W674 was used in this study. The vaccine
was prepared with heat killed organisms (HKO) of W674 grown in NB
by the methods described in sections 2.3.1 and 2.4.3 (a).
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5.1. Vaccination and Challenge of mice
Swiss white mice of either sex at 4-6 weeks of age were
allocated randomly into four groups of fifteen (Table 5.1).
Animals in groups two and three were vaccinated with 0.2 ml of HKO
vaccine s.c. on days 0 and 14. Mice in groups one and three were
challenged i.p. with a 10 LD,_q of a 6h broth culture of W674 on day
g
28. The challenge inoculum contained 3.0 x 10 cfu/0.1 ml which was
approximately the 10 for this strain as determined by
Abdullahi (1987). Group four mice were included as untreated
controls.
In this experiment all fifteen mice in group one died within 24h
of challenge. In contrast, none of the vaccinated mice in group 3
died after challenge. The HKO vaccine, therefore, gave 100%
protection against a challenge producing 100% mortality.
a) Immune mouse sera
The surviving mice were killed by placing them in a carbon
dioxide chamber 48h after challenge. Blood from each mouse was
collected from the inferior vena cava and serum was separated. The
individual mouse serum samples were stored at -20°C until used.
5.2. Bactericidal assay
The assay was performed according to the method described by
Sutherland (1988).
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Table 5.1. Vaccination, challenge and time of bleeding of
groups of mice.
Vaccinated Infected Bled
Group Day 0 Day 14 Day 28 Day 30
1 - - + - *
2 + + - +
3 + + + +
4 +




a) Preparation of bacterial inoculum
Two to three colonies removed from a SBA plate were inoculated
into 10 ml NB and incubated for 18h at 37°C with shaking. A log
phase culture was obtained by inoculating 100 ^il from the 18h broth
culture into another 10 ml NB and incubating for 3h at 37°C with
shaking. Bacteria pelleted from 1 ml aliquots from 3h culture by
centrifugation at 11,000 g for 5 min on a microfuge, were washed 3
times by centrifugation in modified barbitol buffer (MBB) (Oxoid,
UK). After the final wash, bacteria were resuspended in 1 ml of
MBB and tenfold serial dilutions were made in the same buffer. The
aggregated colonies were dispersed by placing the bacterial
suspensions in a sonicating waterbath for 10 min at 37°C. These
bacterial suspensions were used as assay inocula in the
optimisation of this test. Bacterial counts on these suspensions
were made by the method of Miles and Misra (1938) .
b) Standard positive serum
Hyperimmune serum against strain W674 produced (in rabbits) by
the method described in section 2.5 was used as the standard
positive serum.
c) Standard negative serum
Fetal bovine serum (FBS) tested and proved to be free of
bactericidal antibody to P. multocida was used as a negative
control.
The standard sera and test samples were heat- inactivated at
56°C for 30 min before assay to destroy endogenous complement.
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d) Source of complement
Sera from new born calves or gnotobiotic lambs were tested for
adequacy of complement activity by their ability to cause 100%
killing of bacteria in the presence of the standard positive serum,
and the absence of bactericidal antibodies. Complement was stored
at -70°C until used.
5.2.1. Optimisation of bactericidal assay
Initially, optimal conditions for the demonstration of antibody
mediated complement-dependent killing of P. multocida were
determined with respect to bacterial concentration, incubation
period and concentration of standard sera.
Standard sera (20 pi) were added in triplicate to wells of
sterile, tissue culture grade microtitre plates (NUNC, Denmark). P.
multocida bacterial inoculum (100 jul) in MBB was added to each
triplicate assay well and plates were incubated at room temperature
for 10 min. The complement source (80 pi) was then added to each
well, (except when evaluating the effect of antibody on P.
multocida in the absence of complement and the effect of complement
alone on P. multocida, when 80 pi of heat-inactivated complement
and 100 pi fresh complement were added respectively).
Plates were sealed with plastic film (Flow Laboratories, Irvine,
UK) and incubated at 37°C. Volumes (10 pi) of each assay
suspension were then removed with a multichannel pipette and
inoculated on 12 x 12 cm square (Sterilin Ltd, Feltham, UK) SBA
plates. When bacterial counts were too high for direct plate
counting, as when the optimisation of the bacterial inoculum was
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being carried out, 1 in 10 and 1 in 100 dilutions of each
suspension were made in MBB diluent in microtitre plates before
direct plating. The SBA plates were allowed to dry and then
incubated at 37°C overnight.
The initial (Tq) bacterial count in each assay suspension was
calculated as 0.5 x the mean cfu/ml determined in the assay
inoculum. The mean cfu/ml of assay suspension remaining after 30
min (T^q) was calculated from the mean number of colonies counted
in each triplicate 10 p.1 volume. The mean percentage of inoculum
killed (%) of each serum sample was then calculated from the
formula: K = 1-[mean cfu/ml at T^q/ mean cfu/ml at T ] x 100.
In this in vitro assay very little variations in counts between
sample triplicates were found. The standard positive and negative
sera gave reproducible results i.e. 100 and 0% K, respectively at
every test.
The standard positive serum gave 100% killing of bacterial
3
suspensions containing < 1.06 x 10 cfu/ml. Killing dropped to
L\.
97.5% and 80.9% when the suspension titre was 1.06 x 10 and 1.06 x
10^ cfu/ml respectively and no killing was observed when the
suspension titre was > 1.06 x 10^ cfu/ml.
The optimal bacterial inoculum was therefore selected as 2.0 x
3
10 cfu/ml since this was totally killed by the standard positive
serum and gave the maximum number of colonies which could be
counted readily.
The 100% killing of P. multocida by the standard positive serum
occurred only in the presence of complement. Any dilution of
heat-inactivation of the complement source abolished its activity
completely.
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The standard negative serum plus complement was not bactericidal
at any dilution, while the standard positive serum remained up to
90.6% bactericidal from 1 in 2 to a 1 in 16 dilution. At higher
dilutions, activity dropped rapidly from 81.2% to 21.4% at 1 in 32
and 1 in 64 dilutions respectively.
After 2 min incubation only 2.6% killing occurred in the
presence of the standard positive serum. At 10 and 20 min
incubation 84.3 and 93.8% killing occurred. At and beyond 30 min
the percentage killing was 100, and an incubation period of 30 min
was therefore selected as optimal.
Optimal conditions for assay of bacterial killing of P.
multocida were therefore found to be 20 pi of undiluted test serum
3
with 100 jul of 2 x 10 cfu/ml of bacteria, mixed with 80 pi of
undiluted fresh complement and incubation at 37°C for 30 min.
5.2.2. Determination of bactericidal activity of immune
mouse sera
Employing the optimal conditions described above, the assay was
performed with individual mouse serum samples. In order to adjust
3
the assay inoculum to 2.0 x 10 cfu/ml, a standard curve of cfu/ml
against optical density of the bacterial suspensions at 420 nm was
initially used. A variation of one log unit in the colony count
occurred, affecting the efficiency of the assay. P. multocida when
o 9
grown in NB for 6h at 37 C gave a colony count of 5.0 x 10 cfu/ml
consistently. Similarly, a log phase culture grown for 3h at 37°C
g
as described previously, resulted in 3.0 - 5.0 x 10 cfu/ml.
Based on this criterion, the bacterial inoculum was diluted with
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MBB to 2.0 x 10 cfu/ml thereby introducing very little variation
in the count in the assay.
Bactericidal capacities of sera from groups 2, 3 and 4 are
indicated in Table 5.2. The results will be interpreted later in
the text.
5.3. Determination of antibody response of mice to P. multocida by
indirect ELISA
Antibodies to P. multocida in mouse serum samples were detected
by ELISA. P. multocida cell suspension used as the antigen was
diluted 1 in 100 in carbonate/bicarbonate buffer pH 9.6, while each
serum sample was diluted 1 in 100 in PBS/Tween. Table 5.2
indicates the ELISA titres of sera from groups 2, 3 and 4.
5.4. Statistical analysis
The Mann Whitney ranking test was used to determine significant
differences between the groups, while the data were correlated by
the Spearman-Jackson rank correlation test.
5.4.1. Analysis of immune mouse sera for the bactericidal activity
and ELISA titres
The mean bactericidal capacities and ELISA .titres of groups 2
and 3 (Table 5.2) were not significantly different from each other.
Both groups had raised serum bactericidal capacity and ELISA titres
compared to the unvaccinated (group 4) mice which had no
bactericidal capacity and significantly lower ELISA titres (P <
0.001).
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Table 5.2. Bactericidal capacities (% K) and ELISA optical
densities of immune mouse sera
Animal Group 2 Group 3 Group 4
No. (Vaccinated (Vaccinated and (Unvaccinated
only) challenged) unchallenged)
%K* Elisa OD %K Elisa OD %K Elisa OD
1 NA NA NA NA 0 0.000
2 4 0.242 70 0.148 0 0.000
3 60 0.200 44 0.181 0 0.032
4 70 0.220 44 0.148 0 0.026
5 84 0.127 74 0.259 0 0.017
6 74 0.205 80 0.222 0 0.006
7 80 0.155 60 NA 0 0.017
8 84 0.166 84 0.337 0 0.007
9 77 0.222 94 0.306 0 0.001
10 57 0.142 77 NA 0 0.000
11 84 0.106 74 NA 0 0.000
12 60 0.175 87 0.249 0 0.000
13 57 0.197 54 0.113 0 0.053
14 50 0.219 97 0.119 0 0.039
15 60 0.199 70 0.151 0 0.054
group mean 64.4 0.1839 72.1 0.2030 0 0.0168
(±S.E.) (±5.6) (±0.04) (±4.5) (±0.08) (±0.02)
NA - Not available
* %K — 1 - [mean cfu ml ^ at T^/mean cfu ml ^ at To] x 100
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Bactericidal capacity of serum samples correlated well with
ELISA titres (P < 0.001).
5.5. Phagocytosis assay
This was performed in collaboration with A.D. Sutherland,
employing the optimal conditions described for P. haemolytica by
Sutherland (1989, Thesis in preparation).
5.5.1. Bacterial inoculum
P. multocida (W674) inoculum for the assay was prepared from an
18h 3H-thymidine labelled culture and adjusted to the required
concentration as described by Sutherland (1989) . The bacterial
count in the suspension was confirmed by the dilution method of
Miles and Misra (1938) .
5.5.2. Decapsulation of P. multocida
The method described by Maheswaran and Thies (1979) was
followed, for the decapsulation of P. multocida. 3H- thymidine
labelled P. multocida W674, pelleted from a 1 ml sample of 18h
broth culture was resuspended in 1 ml of PBS at pH 6.0. The
bacterial suspension in PBS was mixed with 1 ml of PBS (pH 6.0)
containing 5000 National Formulary Units of testicular
hyaluronidase (Sigma) and incubated at 37°C for 3h. Decapsulated
bacteria were removed by centrifugation at ll,000g for 5 min,
washed three times in Hank's Balanced Salt Solution (HBSS) and
resuspended in "Hanks medium" to the required concentration. The
Hanks medium was prepared by supplementing HBSS with 10%
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heat-inactivated fetal bovine serum, 2% 30 mM Hepes buffer, 1%
sodium bicarbonate and adjusted to pH 7.2 with 1M NaOH. The number
of bacteria in the suspension was confirmed by retrospective plate
counting on SBA.
5.5.3. Recovery of mouse peritoneal macrophages
Six mice (Swiss white/Balb/c crosses) were each inoculated
intraperitoneally with 2.0 ml of Bayol (Esso). The mice were killed
by placing them in a carbon dioxide chamber 48h after
inoculation and the peritoneal cavities were washed several times
with HBSS after opening the abdominal walls. The HBSS containing
peritoneal macrophages was collected by sterile pipettes into
sterile universal bottles. The cells recovered by sedimentation at
lOOg for 10 min at room temperature were washed three times with
HBSS and finally resuspended in 1 ml of Hanks medium. An aliquot
(10 pi) of cells was added into 90 ul of Trypan blue dye (BDH) and
the number of viable macrophages and the total number of cells were
counted in an improved Neubauer cell counting chamber. The
peritoneal macrophages recovered by this way were 96% viable and
consisted of greater than 80% of the cell population as assessed by
morphological criteria. The number of macrophages recovered were
2.25 x 10^ in the total volume of 1.5 ml, and was adjusted to give
2.5 x 106 cells/ml.
5.5.4. Sera tested in the phagocytosis assay
a) Standard positive serum
Sera from mice implanted with chambers containing live P.
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multocida (Section 3.1.a) were used as the standard positive serum
in this assay. Blood was collected from mice 30 days after the
implantation of chambers and the serum was separated and stored at
20°C until used.
b) Standard negative serum
Sera from normal, healthy, six week old mice were used as
standard negative serum.
c) Immune mouse serum
Most of the serum samples in groups 2, 3 and 4 (Section 5.1,
Table 5.1) were not available in sufficient volumes to be tested
individually for phagocytic activity. Pooled serum samples were
therefore made from each group by mixing the equal numbers of
serum samples to give equal final volumes.
All the serum samples were heat-inactivated at 56°C for 30 min
before use.
5.5.5. Determination of the ability of immune mouse sera to
enhance phagocytosis of P. multocida by mouse peritoneal
macrophages
This was performed essentially according to the method described
by Sutherland (1989 Thesis in preparation).
In order to study the effect of decapsulation of P. multocida on
phagocytosis, the assay was carried out under the conditions
described below, with hyaluronidase treated bacterial suspensions.
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The assay was performed in microtitre SV filtration plates
(Millipore, USA) using the Titertek vacuum apparatus (Millipore,
USA) .
The microtitre plate filter membranes with a pore size 5.0 pM
were wetted by the addition of 10 pi of Hanks medium to each assay
well. The bacterial suspension in 100 pi volumes were added into
each assay well except for three blank control wells which received
120 pi of Hanks medium. At the same time the bacterial suspension
was also added in triplicate in 100 pi volumes to 2 ml of
Scintilator 299 (Packard Instrument Co, USA) in plastic vials.
These were counted as total activity controls on a B-isotope
counter (Canberra Packard, U.K.).
The test sera and positive and negative control sera were then
added in 20 pi volumes into triplicate assay wells. The plates
were sealed with sterile plastic films and incubated at 37°C for 30
min to allow opsonisation to occur. The suspension of mouse
peritoneal macrophages was then added in 80 pi volumes into each
assay well except the bacteria only control wells which were
inoculated with 80 pi of Hanks medium. Plates were again covered
with sterile plastic film and incubated at 37°C for 30 min to allow
phagocytosis to occur.
Bacteria that were not engulfed by peritoneal macrophages were
removed by suction placing assay plates on the Titertek vacuum
apparatus. This was followed by washing each well five times with
200 pi of HBSS. The retained peritoneal macrophages containing
engulfed bacteria were dried onto membrane filters by placing assay
plates at 37°C overnight in an incubator. Individual well filter
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membranes were punched out and added into 2 ml of scintillant in
plastic vials. Activity was counted on a B-isotope counter.
In this assay P. multocLda bacterial suspensions, both
capsulated and decapsulated,contained 3.0 x 10^ cfu/ml, giving a
ratio of 15:1 of bacteria to macrophages.
The percentage of bacteria in the suspension that were
phagocytosed was calculated from the formula:
% phagocytosis = 100 x
The mean counts per min (cpm) in test sample - the cpm in
bacteria only
The mean cpm in the bacterial inoculum - the cpm in
bacteria only
Table 5.3 indicates the percentage phagocytosis in each pooled
immune mouse serum sample. The percentage phagocytosis in sera of
mice which were challenged after vaccination (group 3) was slightly
higher than that of mice which were vaccinated only (group 2).
Decapsulation of bacteria by treatment with hyaluronidase seemed to
have no effect on the % phagocytosis. The % observed in the
bacteria only and the blank controls ensured that the extracellular
bacteria had been removed from assay suspensions. The low
percentages of phagocytosis in this study may have resulted from
the high ratio of bacteria to macrophages.
DISCUSSION
A vaccine of heat-killed organisms (HKO) of P. multocLda type A
induced 100% protection in mice against a homologous challenge of
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Table 5.3. The ability of immune mouse serum to
enhance phagocytosis of P. multocida



























10 which gave 100% mortality in the unvaccinated control
group. Although P. multocida is very virulent for mice, excellent
protection against parenteral infection was attained by others
(Woolcock and Collins 1976) using injections of HKO vaccine
incorporated into Freund's complete adjuvant. Humoral immunity and
the possible involvement of polymorphonuclear leucocytes has been
implicated in protection of effectively immunized mice (Collins and
Woolcock 1976) ; but the mechanisms of immunity were not examined.
The experiments described here were designed to study the
mechanisms of immunity by which immune mouse serum overcomes
infection with particular reference to mechanisms such as the
complement-mediated, antibody-dependent killing of bacteria and the
augmentation of phagocytosis by mouse peritoneal macrophages.
In this study protection against P. multocida was clearly
associated with bactericidal antibodies produced by vaccination.
Unvaccinated, susceptible control mice had no bactericidal
antibodies while vaccinated protected mice did have bactericidal
antibodies.
During the optimisation of the bactericidal assay both
complement and specific antibodies were found to be essential
components indicating that this activity was operating via the
classical pathway of complement activation and that in the absence
of antibody the alternative pathway was not activated. Antibody-
mediated killing by the classical pathway of complement therefore
appears to be an important mechanism of immunity against P.
multocida and can be stimulated by vaccination.
108
The results also suggested that immune mouse serum was capable
of enhancing phagocytosis of P. multocida by peritoneal
macrophages. Absence of any phagocytosis with non-immune serum and
the enhanced phagocytosis by immune serum confirmed the role of
specific antibodies as opsonins in the process of phagocytosis.
The slightly higher percentage phagocytosis observed in the serum
of mice which were challenged may possibly be due to an anamnestic
response within 48h or may be due to a unique response towards the
virulent organisms. The response induced against the live
organisms during the 48h after challenge may be an absolute
requirement for the activation of the macrophages and/or the
opsonization of bacteria by specific antibodies which enhanced
phagocytosis.
The assay had to be performed with pooled serum samples because
of the non-availability of certain individual mouse serum samples.
Significant differences between groups and correlations of data
could not be evaluated because of the small sample size. It was
clear, however, that vaccination induced antibodies which enhanced
but
phagocytosis£_whether this correlated with protection could not be
studied.
Anti-phagocytic activity of the hyaluronic acid capsule of P.
multocida was reported by Maheswaran and Thies (1979) and Anderson
et al (1984). Removal of this capsule might therefore, make the
bacteria more susceptible to phagocytosis. In this study,
decapsulation of bacteria by hyaluronidase treatment did not
influence the phagocytosis revealing that the hyaluronic acid
capsule in fact was not anti-phagocytic. Consistent with this
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observation was a report by Ryu et al (1984) that a component of
the capsule other than the hyaluronic acid was responsible for the
anti-phagocytic effect of P. multocida. However, without proving
that hyaluronidase treatment removed the capsular hyaluronic acid
completely, it is not possible to rule out its anti-phagocytic
effect.
The reported ability of non-immune serum to opsonize rabbit
isolates of P. multocida as effectively as immune serum indicates
that non-specific opsonins, such as cross- reacting antibodies may
play a role in enhancing phagocytosis (Hofing et al 1979, Rush et
al 1981). In this context, the involvement of the specific
antibodies in the control of P. multocida infection was unclear.
Resistance of P. multocida type D rabbit isolates to
polymorphonuclear neutrophil phagocytosis (Anderson et al 1984,
Rush 1989) suggested the involvement of immune mechanisms other
than phagocytosis in combatting the virulent organism.
That cell-mediated immunity (CMI) was also involved in
protection can not be discounted, but Carter (1967), Woolcock and
Collins (1976) and Collins and Woolcock (1976) have all indicated
that protection of mice with P. multocida vaccines is due to
humoral immunity alone and classical CMI was therefore not
investigated in this present study.
The results of this study suggest that in mice, the
complement-mediated antibody-dependent killing of P. multocida is
an important mechanism of immunity. It may be worthwhile
investigating whether HKO vaccines stimulate bactericidal
antibodies in cattle and whether the stimulation of these
antibodies correlates with immunity.
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The bactericidal capacity of sera correlated (P < 0.001) with
their ELISA titres to whole-cell antigen suggesting that this rapid
simple ELISA may be useful in screening vaccinated animals for
protective antibody. The correlation of bactericidal capacity with
whole-cell ELISA titres suggested that cell-surface antigens were
involved in stimulating bactericidal antibodies. Examining the
ability of individual cell-surface antigens to raise bactericidal




Production and Characterization of Monoclonal Antibodies Against
Pasteurella multocida type A.
INTRODUCTION
The immune response of P. multocida in mice is directed
primarily against components of the cell surface i.e. capsule,
LPS and OMP. Attempts at identifying single protective antigens
employing mouse immune serum were unsuccessful due to the
polyclonal nature of the serum.
One possible way to overcome this problem is by producing
monoclonal antibodies (mAb) against cell surface antigens and
evaluating the significance of such mAbs in immunity to P.
multocida. Whether the mAb protects mice can then be determined by
a passive mouse protection test (Moreno et al, 1983). If any mAb
appears to protect mice, it is important to identify the mechanism
by which the antibody mediates immunity. By binding to a cell
surface component, antibody can enhance phagocytosis, fix
complement resulting in lysis or disrupt the metabolic processes of
bacteria resulting in death (Penaredondo et al 1988; Sutherland
1988; Coulton 1982).
Monoclonal antibodies can also be used for various other
purposes. They have been employed for serotyping (Lam et al 1987)
and for purification of antigens by affinity chromatography
(Staehelin et al, 1981). In a sandwich or capture ELISA the
specific antigen is captured by the mAb precoated onto the wells.
This technique can be used to detect a specific antigen in a
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suspected specimen (Hancock and Poxton 1988) or to measure the
antibody status of animals to a particular organism (Shankarappa et
al 1989a). Furthermore, it can be employed as a tool to evaluate
cross-protection between strains or related species of bacteria (Lu
et al 1988).
In this present study, the aim was to raise mAbs against P.
multocida cell surface components. Upon characterization, their
immunological mechanisms were investigated.
Mechanisms of hvbridoma production
Spleen cells from mice immunized with antigen are fused with
plasmacytoma cells in the presence of polyethylene glycol (PEG).
Spleen cells die in tissue culture medium. Plamsacytoma cells
which are defective in the enzyme hypoxanthine guanine
phosphoribosyltransferase (HGPRT) die in the tissue culture medium
supplemented with hypoxanthine, aminopterin and thymidine (HAT).
Aminopterin blocks the synthesis of purines and pyrimidines. Only
spleen cell/plasmacytoma hybrids survive in HAT medium. The
contribution of the enzyme HGPRT from spleen cells enable the
hybrids to utilize extraneous hypoxanthine to synthesise purines.
Adding thymidine to culture medium makes it possible for hybrids to
synthesise thymidine 5'-monophosphate (TMP) utilizing thymidine
kinase (TK).
RESULTS
Part 1 - Production and characterization of monoclonal antibodies
against P. multocida type A.
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6.1. Production of monoclonal antibodies
6.1.1. Bacterial strain
P. multocida type A (W674) was used to immunize mice.
6.1.2. Preparation of immunizing agent
P. multocida grown overnight at 37°C in nutrient broth
containing 2,2'-dipyridyl, were washed once in PBS and divided into
2 aliquots. One aliquot was resuspended in PBS to give a bacterial
9
count of 8.0 x 10 cfu/ml. The remaining aliquot was resuspended
9
in distilled water to contain 1.0 x 10 cfu/ml (vaccine 2). Both
cell suspensions were killed by heating at 60°C for 90 min. The
cell suspension in PBS was emulsified with an equal volume of
Bayol/Arlacel. One part of the emulsion was then mixed with 3
parts of 1 in 10 alhydrogel (vaccine 1). The final inoculum of
g
both vaccines therefore, contained 10 cfu/0.1 ml.
6.1.3. Mice
Six weeks old female Balb/c mice were used
6.1.4. Immunization Protocols
Two groups of five mice were each immunized with vaccine 1 or
with 2 according to the following protocols.
a) Protocol 1
Day 0 - 0.1 ml vaccine 1 was inoculated intraperitoneally into 5
mice <
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Day 14 - 0.1 ml vaccine 1 was inoculated intraperitoneally
Day 22 - Test bleed - Blood was collected from the tail vein
b) Protocol 2
Day 1 - 0.1 ml vaccine 2 was inoculated intraperitoneally into 5
mice.
The inoculations were repeated on days 2, 3, 8, 9, 10 and 22.
A test bleed was performed on day 29.
6.1.5. The immune response of mice to vaccines 1 and 2
The antibody response of each mouse was determined by whole cell
ELISA (section 4.3.2.b ii and is indicated in figs 6.1.A and B) .
Doubling dilutions of serum were tested against NB 2,2'-dipyridyl
grown cells.
Mouse no. 5 which had the highest antibody titre was selected
g
for fusion and was boosted with 10 heat killed organisms in 0.1 ml
saline intravenously 3 days prior to fusion.
6.1.6. Preparation of spleen cells for fusion
The mouse was sacrificed 3 days following intravenous boost and
the spleen removed asceptically into 6 ml RPMI 1640 medium. The
spleen was homogenized and the resulting cell suspension was washed
three times by centrifugation at 450 g for 10 min, with RPMI 1640
medium and resuspended in 10 ml of basic medium (section 2.7.1.).
Fig. 6.1. Immune response of mice to vaccines 1 and 2 as
determined by indirect ELISA
A) Response of mice to vaccine 1
B) Response of mice to vaccine 2
(Two mice were culled due to poor condition)
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Fig. 6.1 Immune Response of Mice to
Vaccinas 1 & 2 as determined by ELISA
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6.1.7. Preparation of NS-0 for fusion
NS-O, a mouse plasmacytoma cell line was selected as a fusion
partner for mouse spleen cells as this line does not make or
secrete H or L chains. One week prior to fusion, 2 or 3 vials of
NS-0 cells were taken from liquid nitrogen and thawed at 37°C and
inoculated into 20 ml of RPMI 1640 supplemented with 10% FCS
(section 2.7.2.). After 24h 30 ml of fresh medium was added. A log
phase growth was maintained to be used in the fusion. On fusion
day, adherent NS-0 were harvested by incubating for 10-15 min at
room temperature with 10 mM EDTA in PBS (section 2.7.8.) washed
twice in RPMI by centrifugation at 180 g for 5 min and resuspended
to 10 ml in basic medium.
6.1.8. Fusion protocol
Fusion was performed according to the principle described by
Kohler and Milstein (1975) except that polyethylene glycol (PEG)
was the fusion agent.
1. NS-0 and spleen cell suspensions were counted in an improved
Neubauer haemocytometer under uv light by mixing a 10 ul sample of
each with an equal volume of acridine orange. The number of cells
in each cell suspension was then calculated.
The following cell counts were obtained: spleen cells 1.1 x
10^/ml. Two flasks of NS-0 contained A - 1.1 x 10^/10 ml and B -
4.6 x 106/10 ml
2. Appropriate numbers of spleen cells and NS-0 (spleen cells:
NS-0 ratio in A 5:1 and in B 12:1) were combined and centrifuged at
450 g for 5 min.
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3. 1 ml of PEG (in 50% RPMI at pH 8.5, section 2.7.6.) at 37°C
was added to the cell pellet over 2 min, swirling gently to
resuspend cells and the suspension centrifuged at 140 g for 5 min.
4. Over 2 min, 5 ml basic medium was then added without
disturbing the pellet. The cells were resuspended by swirling
gently over another 3-4 min and centrifuged at 300 g for 5 min.
5. The supernate was poured off carefully and 5 ml 20% FCS in
HAT (section 2.7.3.) added without disturbing the pellet. After
leaving for 7 min, cells were resuspended and adjusted to a cell
concentration of 2 x 10^ cells/ml with 20% FCS in HAT.
6. Cell suspensions (100 ul containing 2 x 10^ cells per well)
were dispensed into the inner 60 wells of 96 well tissue culture
plates which contained 100 ul of 1 in 3 mixed thymocyte medium (MTM
section 2.7.5.) in 20% FCS/HAT medium as the feeder layer. The
plates were placed in a box and incubated with humidity and 5% CO^
at 37°C. The wells were examined for hybrids on day 7 after fusion
and fed with 100 jal of 20% FCS/HAT. Supernates (100 jal) of 97
hybrids which were at least 10% confluent were removed and screened
against whole cells by ELISA for specific antibody production.
Supernates of 20 hybrids gave optical densities of greater than
0.5 (see appendix 1.2). These hybrids were expanded from pots to
flasks and the serum content of medium was reduced gradually from
20% to 15% to 10% (section 2.7.2.).
6.1.9. Cloning
Healthy growing hybrids were cloned by limiting dilution at 1
and 10 cells/well in 20% FCS containing 1 in 3 MTM. Clones were
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tested for antibody production by testing the supernates against
whole cells by ELISA. Only eight cell lines were found to be
producing antibodies (appendix 1.3).
6.1.10. Freezing of cells
Several vials of cells from every line were frozen when they
reached a sufficient density (10^ - 10^ cells per flask). Cells
resuspended in freezing medium (section 2.7.7.) were frozen at
-70°C overnight and then transferred to liquid nitrogen.
6.1.11. Production of ascites in mice
Adult Balb/c female mice were inoculated intraperitoneally with
0.5 ml Pristane (2, 6, 10, 14- tetramethylpentadecane - Sigma).
Three days later, lO'' cells from the required cell line were
inoculated intraperitoneally into these mice. Ascitic fluid was
collected by inserting a needle (23 gauge) into the peritoneum
allowing fluid to drain into a sterile bijoux bottle. The fluid
was clarified by centrifugation and stored at -20°C until used.
6.2. Characterization of monoclonal antibodies
6.2.1. Class and subclass determination
Determination of class and subclass of the culture supernates
was performed using the mouse monoclonal antibody isotyping kit
(Amersham International pic, Amersham, UK) according to the
manufacturer's instructions. Table 6.1 gives the isotypes of the
antibodies from the culture supernates.
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Western blots of whole cell lysates, OMP and LPS (proteinase k
digests) of W674 bacteria grown in NB containing 2,2'-dipyridyl
were prepared by the methods described in sections 2.6.3. and
2.6.4. The NC strips were then probed with culture supernates.
Fig. 6.3, 6.4 and 6.5 demonstrate the results of whole cells, OMP
and LPS blots respectively.
The antibodies secreted by 1/4-1-6 cells were directed against
the 77 kDa protein, while antibodies of 1/8-16-11 were found to
react with the LPS. The remaining six did not react with proteins
or against LPS in Western blotting.
6.2.3. Indirect Haemagglutination Test (IHA)
Each mAb (ascitic fluid) was tested by the method described in
section 2.6.1. The antigen was prepared from strain W674, the
homologous immunizing strain. The test was performed with a series
of doubling dilutions from 1 in 2 to 1 in 128 of each mAb. Fig.
6.6. shows the haemagglutination ability of each mAb. Only one mAb
- 1/2-16-8 demonstrated haemagglutination to a titre of 1 in 64 and
was considered to be reactive against a component of the capsule,
as it did not react with LPS in the Western blot.
The specificity of the anti-capsule mAb was studied by testing
it against fifteen different strains of P. multocida in IHA. The
crude capsular extract of 15 strains was prepared by the method in
section 2.3.2. The test was performed according to the method
given in section 2.6.1. using 1 in 4 dilution of the mAb. The
reactivity of the mAb against each strain was compared with that of
Fig. 6.3. Western blots of W674 whole cell lysate probed
with neat monoclonal antibody culture supernates:
a. 1/2-16-8; b. 1/4-1-5; c. 1/4-1-6;
d. 1/8-16/11; e. 1/13-6-12; f. 1/15-9-1;
g. 1/18-13-5; h. 1/19-12-13; i. 1/20-15-15;
j. standard positive serum (from the mouse
used for fusion); k. standard negative (culture
medium 10% FCS).
Fig. 6.4. Western blots of outer membrane proteins of
W674 probed with neat monoclonal antibody
culture supernates. a. 1/8; b. 1/8-15;
c. 1/8-16-11; d. 1/18-5; e. 1/18-13-5;
f. 1/20-16; g. 1/20-10-15; h. 1/19-11;
i. 1/19-12-13; j. 1/13-6 ; k. 1/13-6-12;
1. 1/2-15; m. 1/2-16-8; n. 1/4-1-6;
o. 1/15-9-1; p. standard negative (culture
medium 10% FCS); q. standard positive serum
(from mouse used for fusion)
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Fig. 6.5. Western blots of LPS (proteinase k digests)
of W674 probed with neat monoclonal antibody
culture supernates. a. 1/2-16-8; b. 1/4-1-6;
c. 1/8; d. 1/8-15; e. 1/8-16-11;
f. 1/13-6-12; g. 1/15-9-1; h. 1/15-9-6;
i. 1/18-13-5; j. 1/19-11; k. 1/19-12-13;
1. 1/20-10-15; m. standard negative (culture
medium 10% FCS); n. standard positive serum
(from the mouse used for fusion)
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hyperimmune rabbit serum diluted 1 in 500 in PBS. Table 6.2
indicates the strains tested and summarizes the results. The type
of haemagglutination demonstrated by both mAb and hyperimmune
rabbit serum are shown in fig. 6.7.
It was evident that the haemagglutinating ability of the
anti-capsule mAb was distinctly different from that of the
polyclonal serum. The mAb demonstrated agglutination only with the
homologous strain. A slight agglutination was observed with
reference types A (10322) and D (10325).
6.2.4. Bactericidal activity of monoclonal antibodies as
determined bv in vitro assay
The bactericidal capacity of each mAb was tested by the method
described in section 5.2.1. using the ascitic fluid. Sera from
gnotobiotic lambs were used as the source of complement (section
5.2 (d)). The bacterial strain used was P. multocida W674, the
homologous immunizing strain.
Complement-mediated bactericidal activity was demonstrated only
by the anti-LPS mAb (1/8-16-11), which killed 80% of P. multocida
organisms. The standard positive serum gave 100% killing while no
bactericidal activity was observed with standard negative serum
(fig. 6.8).
6.2.5. Ability of mAbs to protect mice passively
The protective capacity of the mAbs was studied by the passive
mouse protection test (PMPT) using Balb/c mice. Each mAb (0.2 ml)
in the form of ascitic fluid was inoculated intra-peritoneally
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Table 6.2. Haemagglutination property of the anti-
capsule mAb against fifteen different
strains of P. multocida in comparison to
the polyclonal hyperimmune serum.








Type D ± -
Type E - -
X12 (bov. A) - +
X1053 (bov. A) - +
W666 (bov. A) -
X109 (bov. A) -
W829 (bov. A) - +
X110 (bov. A) +
X1016 (bov. A) - +
X200 (bov. A) - +
X9 (bov. A) - +
W669 (bov. A) +
W674 (bov. A. homologous) + +
+ - agglutination
+ - very slight agglutination
- no agglutination
bov. A - bovine type A
Fig. 6.6. The ability of monoclonal antibodies to
agglutinate sheep red blood cells coated with
heat-extracted capsular antigen (indirect
haemagglutination). Row a, 1/2-16-8;
b. 1/4-1-5; c. 1/8-16-11; d. 1/13-6-12;
e. 1/15-9-1; f. 1/18-13-5; g. 1/19-12-13;
h. 1/20-10-15; i. antigen coated red blood
cells only (no monoclonal antibodies)
Fig. 6.7. Indirect haemagglutination of heterologous
strains of P. multocida by (a) the
anti-capsule monoclonal antibody (ascitic
fluid) and (b) the polyclonal hyperimmune
rabbit serum.
®©®©®©©®®®®©
© © © ®
1. Type A (10322) 9. W829
2. Type B (10323) 10. X110
3. Type D (10325) 11. X1016
4. Type E (10326) 12. X200
5. X12 13. X9
6. X1053 14. W669
7. W666 15. W674






into five mice at Oh. Another group of five mice, used as the
controls, received 0.2 ml (ascitic fluid) of a mAb - raised
against louping-ill virus. One hour later, all mice were
challenged intra-peritoneally with 0.2 ml of the bacterial
g
suspension containing 2.0 x 10 viable P. multocida. This
challenge inoculum consisted of approximately 10 LD^q. Mice were
observed for up to 48h after challenge, deaths were recorded and
the percentage protected was calculated. Table 6.3 indicates the
protective capacity of mAbs as determined by the PMPT.
Of the mice surviving after challenge, only those which
received anti-LPS mAb were found to be healthy. As the other mice
showed severe illness, they were killed by cervical dislocation
prior to the completion of the observation period.
Lack of growth of P. multocida in the heart blood plated onto
SBA, of one of the 5 mice which received anti-LPS mAb and
protected against challenge, confirmed the complete clearance of
bacteria from the mouse circulatory system. In contrast, P.
multocida could be re-isolated from heart blood of mice which
received 1/19-12-13, 1/20-10-15 and (controls) mAb (fig. 6.9).
6.2.6. Ability of mAbs to enhance phagocytosis
By employing the methods described in sections 5.5.1 - 5.5.5 the
ability of the anti-capsule and anti-LPS mAb to enhance
phagocytosis by mouse peritoneal macrophages was studied.
Heat-inactivated ascitic fluid of these mAbs were used in this
assay. Decapsulation of P. multocida by incubating bacteria with
hyaluronidase seemed to have no effect on this property of
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Table 6.3. Ability of monoclonal antibodies to protect
mice as determined by passive mouse protection
test.















E7 (control) 0 0
Fig. 6.8. Bactericidal activity (%K) of monoclonal
antibodies as determined by in vitro assay
a b c
1. 1/2-16-8 1/15-9-1 polyclonal immune mouse
serum
2. 1/4-1-6 1/18-13-5 polyclonal hyperimmune
rabbit serum (standard
positive)
3. 1/8-16-11 1/19-12-13 normal mouse serum
4. 1/13-6-12 1/20-10-15 normal rabbit serum
Fig. 6.9. Evidence of complete clearance of bacteria
from the mouse circulatory system by the
anti-LPS monoclonal antibody.
a. Recovery of P. multocida from heart blood
of mouse passively immunized with the
monoclonal antibody 1/20-10-15
b. Recovery of P. multocida from heart blood
of mouse passively immunized with the
monoclonal antibody 1/19-12-13
c. Recovery of P. multocida from heart blood
of control mouse
d. Lack of growth of P. multocida in the heart
blood of mouse passively immunized with the
monoclonal anti-LPS antibody 1/8-16-11.
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phagocytosis. The percentage phagocytosis exhibited by the
anti-LPS mAb in the assay was greater than that of anti-capsule
antibodies. Table 6.4 indicates the percentage phagocytosis of P.
multocida by anti-capsule and anti-LPS mAb and standard mouse
serum.
The two mAbs (1/19-12-13 and 1/20-10-15) that showed some degree
of protection in the PMPT were not included in the phagocytosis
assay as they had not been characterized.
6.2.7. Crossed immunoelectrophoresis of capsular components
by mAbs
The crossed immunoelectrophoresis method described by Hancock
and Poxton (1988) with modifications as to the voltage employed,
was followed.
The antigen used in this study was the crude capsular extract
described in section 2.3.2.
The first dimension gel was prepared by pouring 15 ml molten
agarose onto a 80 mm square glass plate and allowing it to set.
With the aid of a template (fig. 6.10a), wells were cut out and
filled with 15 jul of the antigen. Bromophenol blue (BDH) was
filled into the well at one of the corners and connected the edges
of the gel to the buffer reservoirs with presoaked thick filter
paper. First dimension electrophoresis was performed until the
bromophenol blue reached a length of 9.0 mm in 45 min applying a
voltage of 10 v/cm. The plate was taken out and strips were cut
out. The strips were then carefully transferred to the edge of 50

























































plate as shown in Fig. 6.10 (b) . The second dimension gels were
prepared by adding 300 ul of ascitic fluid of 1/15-9-1, 1/18-13-5
and 1/2-16-8 mAbs and polyclonal hyperimmune rabbit serum into each
of 3 ml molten agarose mixing gently and casting this against the
first dimension strip. Gels were arranged in the tank with the
first dimension strips nearer to the cathode. Wicks were connected
to the reservoirs as above and a voltage of 4 v/cm was applied
overnight.
Fig. 6.10. Templates for crossed Immunoelectrophoresis









The gels were dried according to the method described by Hancock
and Poxton (1988) . When the gels were completely dried, they were
stained for 10 min in Coomassie blue. The backgrounds were cleared
in several changes of the destainer.
The anti-capsule mAb (1/2-16-8) produced a single precipitating
peak while the polyclonal serum produced at least 7 peaks (Fig.
6.11 a & b). This confirmed the heterogeneity of the capsular
extract and the polyclonal serum. The reactivity of the
anti-capsule mAb seems to be directed against a major antigenic
determinant of the capsule. None of the other mAb possessed the
property of precipitation.
Part II. Further studies on the anti-LPS mAb
Results of preliminary work carried out on the mAbs revealed
that antibodies directed against LPS mediated complement — mediated
killing of homologous P. mulCocida and protected mice against a
homologous challenge. As it was the only mAb which protected, it
was decided to study both the strain specificity and structural
specificity of the anti-LPS mAb.
6.3. Comnarison of reactivity of anti-LPS mAb against different
strains of P. mulCocida by indirect ELISA. Western blotting and
bactericidal assay
6.3.1. Screening of P. multocida and other gram-negative organisms
by indirect ELISA
a) Bacterial strains
Fifty different strains of P. mulCocida randomly selected from
Fig. 6.11. Precipitation arcs produced by the
anti-capsule monoclonal antibody 1/2-16-8 (a)
and the polyclonal hyperimmune rabbit serum
(b) in crossed Immunoelectrophoresis. Heat
extracted capsular-antigen (20 ul) run against
300 ul of either monoclonal antibody (ascitic




the culture collection of Abdullahi (1987) including four type
cultures of P. multocida serotypes A, B, D and E (Appendix 2.1)
were tested against the anti-LPS mAb in a whole-cell ELISA. For
comparison, all 16 serotypes of P. haemolytica, seven other
Gram-negative bacteria (Appendix 2.1) and a Gram-positive Listeria
monocytogenes (4B) were also included in this study.
b) Preparation of antigens for ELISA
An overnight culture from each strain grown in nutrient broth
(10 ml) was washed once in PBS and resuspended in 0.5% formal
saline to an absorbance at 420 nm of 0.1. This corresponded
approximately to lO'' cfu/ml. Wells of microtitre plates were
coated with 100 ul of each bacterial suspension by incubating
overnight at 4°C. The assay was then continued as described in
section 2.6.2 with anti-LPS mAb culture supernatant as the primary
antibody. Absorbance at 492 nm was read for each strain and the
percentage absorbance in relation to the homologous strain (W674)
was calculated. Fig. 6.12 shows the reactivity of the anti-LPS
mAb against P. multocida and other Gram-negative bacteria
determined by indirect ELISA.
The anti-LPS mAb recognized its epitope in LPS of 58% of the P.
multocida strains tested (those above 50% absorbance). This
epitope does not appear to be present in the LPS of the other
Gram-negative bacteria tested. It also did not cross-react with any
of the type strains of the four serotypes of P. multocida.
Fig. 6.12. Reactivity of anti-LPS monoclonal antibody
against different strains of P. multocida and
other Gram-negative bacteria as determined by
indirect ELISA. The percent absorbance (OD)
for each strain in relation to the homologous
immunizing strain W674* is indicated.
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c) Selection of strains for Western blotting and for
bactericidal assay
A total of 20 isolates were selected based on the ELISA results,
to be tested by Western blotting and by bactericidal assay. Of
these, 10 strains including the homologous strain gave a percent
absorbance of greater than 60 while the percentage absorbance
indicated by the remaining 10 strains was less than 18.
6.3.2. Reactivity of the anti-LPS mAb against LPS of different
strains of P. multocida by Western blotting
Proteinase K digests of twenty strains were separated on 14%
polyacrylamide gels (without SDS) and transferred
electrophoretically onto NC and probed with anti-LPS mAb culture
supernate as described in section 2.6.4. The same antigens
separated under identical conditions were stained with silver
(Hancock and Poxton 1988) in order to study the pattern of LPS of
each strain.
All the ten strains which gave a percent absorbance of greater
than 60 in ELISA were recognized by the anti-LPS mAb in Western
blotting. The mAb did not react with the LPS of strains that gave
low % absorbance in whole-cell ELISA (figs. 6.13 a and b). The
pattern of LPS of these strains resembled those of semi-rough
strains of enterobacteria (figs. 6.13 c and d).
6.3.3. Bactericidal activity of the anti-LPS mAb against
heterologous strains of P. multocida
This was performed essentially by the method described in
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section 5.2.1. using ascitic fluid and sera from gnotobiotic lambs
as the sources of specific antibody and the complement
respectively. From each bacterial suspension several dilutions
were included in the test, in order to arrive at the optimum assay
3
count which should ideally be 1.0 x 10 cfu/ml. Each strain was
tested against hyperimmune rabbit serum for comparison. Table 6.5
summarizes the results of bactericidal activity of mAb against
different strains of P. multocida. Complement-mediated killing by
the anti-LPS mAb was observed in ten of the twenty strains of P. «
multocida tested. These strains also gave high percent absorbances
in whole-cell ELISA and were recognized by the mAb in Western
blotting. No bactericidal activity was demonstrated by the mAb
against the remaining ten strains tested.
Correlations of % killing and % absorbance were determined by
the Spearman-Jackson rank correlation test and were found to be
highly significant (P < 0.001).
6.4. Study of the anti-LPS mAb for its heterologous protection
by passive protection in mice
The protective capacity of the anti-LPS mAb against heterologous
strains of P. multocida was assayed by the method described in
section 6. For this study, six strains were selected based on
results of the reactivity of the mAb against different strains in
ELISA and Western blotting. Five of these strains reacted well
with the mAb in both tests, while the remaining strain (A848) did
not react with the mAb in either of these tests. The strains were
A36, X110, X1053, A341, A1174 and A848.
Fig. 6.13. a. and b. Western blots of LPS (proteinase k
digests) of heterologous strains of P.
multocida probed with the anti-LPS monoclonal
antibody 1/8-16-11 culture supernate (1 in 2
dilution)
a. Lane 1, A757; 2, A36; 3, X110; 4, X1056;
5, A848; 6, W666; 7, QUO; 8, X1016; 9, W674;
10, X120
b. Lane 1, A341; 2, A1174; 3, A586; 4, A26;
5, A419; 6, X1053; 7, Type A (10322); 8, Type
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Fig. 6.13. (b)
Fig. 6.13. c. and d. LPS (proteinase k digests) of
strains of P. multocida used in fig. a. and
b. stained with silver. c) Lane 1, A757;
2, A36; 3, X110; 4, X1056; 5, X1056; 6, W666;
7, QUO; 8, X1016; 9, W674; 10, X120; 11,
A341; 12, A1174; 13, A586; 14, A26; 15, A419;
16, X1053
d) Lane 1, Type A (10322); 2, Type B (10323);
3, Type D (10325); 4, Type E (10326); 5, X110;








































































































































































6.4.1. Determination of the LD^q of the six strains that were
used in passive mouse protection test
The LE>5qs for all six strains were studied by the procedure
described in section 2.4.2. and are given in Table 6.6.
In the test proper, two groups of thirty Balb/c female mice were
passively immunized at Oh. One group of mice received the anti-LPS
mAb in the form of ascitic fluid while the other group received
ascitic fluid of an unrelated mAb (E^ - against louping-ill virus)
which served as controls. One hour later 5 mice from both groups
were challenged with a 10 LD^q of each strain.
Table 6.7 indicates the number of mice which survived and the
percentage protected on challenge after administration of the mAb
into mice. The control mice which received an unrelated mAb died
after challenge with heterologous strains. The anti-LPS mAb was
not protective against strain A848 which did not react in the
serological assays discussed previously.
6.5. Determination of structural specificity of the anti-LPS
mAb by the inhibition of ELISA
The inhibition of ELISA, which is a modification of indirect
ELISA, according to Hancock and Poxton (1988) can be used to study
the part played by purified antigen or components of antigen in a
complex antigen/antibody reaction. In this technique (fig. 6.14)
the plate is (a) coated with the complex antigen i.e. whole cells
or cell envelope preparation. (b) Antiserum that has been
pre-incubated with a purified component of the complex antigen e.g.

















































































Table 6.7. Protective capacity of the anti-LPS mAb
















to soluble antigen can bind to the immobilized antigen on the
plate. (d) After substrate is added, the colour change is
proportional to antibodies bound to this plate. A low optical
density, therefore reflect the high proportion of antibodies
present in the original antiserum to the specific antigen with
which it is pre-incubated.
Fig. 6.14. Inhibition of ELISA
( a) (b) (c) (d)






This technique was applied to study the specificity of the
anti-LPS mAb using culture supernatant as the source of antibodies.
The complex antigen selected to coat the plate was a cell envelope
preparation. The inhibitors used were the cell envelope
preparation, whole LPS and polysaccharide and lipid A fractions of
the LPS molecule.
6.5.1. Preparation of antigens for the indirect ELISA
a) Cell envelopes
Cell envelopes were prepared from P. mu.ltoci.da W674 grown in NB
containing 2,2'-dipyridyl by the method described under section
2.3.4, stopping the procedure at the stage of pelleting the cell
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envelopes after sonicatlon. The envelope pellet was then washed
twice and resuspended in 3 ml of 0.1M Tris buffer at pH 7.4 and
freeze-dried.
b) LPS
This was prepared essentially by the phenol water extraction
method detailed in section 2.3.3. (a). Since the stability of LPS
is dependent on its salt-form, the LPS was deionized by
electrodialysis and converted to a uniform soluble salt-form as
described by Hancock and Poxton (1988).
c) Deionization of LPS by electrodialysis
The apparatus developed by ISCO for the electrophoretic
concentration of proteins was used for this purpose. The LPS (50
mg), reconstituted in 10 ml of pyrogen-free distilled water, was
electrodialysed under the conditions stated by Hancock and Poxton
(1988) . The insoluble deionized LPS was made into a uniform
suspension by placing it in a sonicating water bath for 5 min. The
pH of the suspension was 3.6 and was at a concentration of 2 mg/ml.
After neutralization with a small drop of 1M triethylamine, the LPS
was made soluble and the pH was found to be 6.9.
d) Preparation of Lipid A
Deionized LPS at a concentration of 2 mg/ml in 1% acetic acid
was heated at 100°C for 90 min. The lipid A was precipitated from
solution and was removed by centrifugation at lOOOg for 10 min.
The supernatant was saved for extraction of polysaccharides. The
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precipitate was washed 3 times with hot distilled water and made
soluble by neutralization with triethylamine and heating at 60°C.
It was then stored freeze dried until required.
e) Preparation of polysaccharide
After removal of the lipid A precipitate from the acid
hydrolysed solution, polysaccharide was extracted from the
solution with an equal volume of chloroform-methanol (2:1 by
volume). The aqueous phase consisting of the polysaccharide
fraction was rotary evaporated to dryness.
The cell envelope preparation, LPS, lipid A and polysaccharide
fractions were reconstituted to 1 mg/ml in PBS before being used in
the assay. The optimum dilutions of the antigen (cell envelopes)
and the antibody (mAb culture supernatant) were determined by a
checker-board titration and found to be both 1 in 32*
6.5.2. The inhibition of ELISA
The wells of a microtitre plate were coated with the cell
envelope preparation diluted 1 in 32 in carbonate/ bicarbonate
buffer, pH 9.6, by incubating overnight at 4°C. The doubling
dilutions of each inhibitor made in PBS were pre-incubated with
equal volumes (200 }il) of 1 in 32 diluted mAb culture supernate for
30 min at 37°C. These pre-incubated samples, as well as the mAb
culture supernate diluted 1 in 32, were added rto the antigen
coated wells after washing the wells. The assay was then continued
as described in section 2.6.2.
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The mean absorbance (OD) of the culture supernatant was taken
from eight readings and was 0.920. The percent absorbance by the
inhibitors at each dilution was then calculated. Fig. 6.15
demonstrates the pattern of inhibition indicated by the complex
antigens and the fractions of LPS. The results show that the
specificity of the anti-LPS mAb is directed towards the lipid A of
the LPS molecule.
6.6. Structure of LPS of P. multocida
The study on determination of the structural specificity of the
anti-LPS mAb by ELISA inhibition suggested that it was directed
against the lipid A moiety of the LPS molecule. This anti-LPS
monoclonal antibody reacted with 58% of P. multocida. strains
examined.
The structural differences of the LPS molecule in relation to
the recognition and non-recognition of strains by the mAb
constituted further investigations in which two strains were
employed: strain W674 against which the mAb were produced and
strain A26 with which the mAb did not react.
6.6.1. Preparation of LPS and fractionation of LPS into Lipid A
and polysaccharide
The LPS of strain W674 and A26 was prepared from 4g dried
bacteria of each strain by the procedure described in section
2.3.3. (a) and yielded 120 and 75 mg dry weight, respectively.
One third of each preparation was used for the analysis of the
whole molecule of LPS. Lipid A and polysaccharide fractions were
Fig. 6.15. Inhibition of ELISA to determine the
structural specificity of this anti-LPS
monoclonal antibody. The 100% value ( — ) was
obtained for the mAb culture supernate by
reacting it at a dilution of 1 in 32 it with
the cell envelope antigen which was coated
onto the plate. The inhibitors were lipid A
fraction ( ) , polysaccharide fraction
( -s- ) of LPS, whole LPS ( -<>- ) and cell-
envelope preparation ( -o- ) .
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Fig. 6.15 Inhibition of indirect ELISA to datarmine
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prepared from the remaining two thirds by mild acid hydrolysis, as
described in sections 6.5.1. (d) and 6.5.1. (e) . These two
fractions and whole LPS were resuspended in pyrogen free distilled
water at a concentration of 5-8 mg/ml.
6.6.2. Chemical analysis on whole LPS. lipid A and
polysaccharide fractions
The chemical analysis on whole LPS, lipid A and polysaccharide
fractions of the two strains for 3-deoxy-D-manno-octulosonic acid
(KDO) carbohydrates and phosphates were carried out by
thiobarbituric acid, phenol/sulphuric and sulphuric/perchloric acid
method respectively as described by Hancock and Poxton (1988) .
Table 6.8 summarizes the results.
The LPS of both W674 and A26 strains were of similar chemical
compositions (Table 6.8).
6.6.3. Separation and quantitation of sugars as their alditol
acetates by gas chromatography
Lipid A was hydrolysed in 4M HCl for 6h at 100°C while the
hydrolysis of polysaccharide was carried out in 2M HCl for 2h at
100°C. Alditol acetates were then prepared from hydrolysed lipid A
and polysaccharide as described by Poxton and Cartmill (1982) and
analysed by gas chromatography.
Sugars of the polysaccharide fraction of A26 and W674 in molar
proportions in relation to heptose calculated from area percentages
are given in Table 6.9.
























































Table 6.9. Comparison of sugar composition of the
polysaccharide fraction of A26 and W674
LPS
Sugar Molar proportions of sugars in
A26 W674








different from one another. The proportion of glucose was nearly 3
or 4 times that of galactose in strain W674 while equal proportions
of glucose and galactose were observed in strain A26 (figs. 6.16 a
and b). P. multocida strain A26 contained galactosamine, which
was absent in strain W674. Both contained glucosamine (figs. 6.17
(a) and (b)).
6.6.4. Analysis of fatty acid composition of lipid A fractions
of W674 and A26 as methyl esters by gas chromatography.
The fatty acids of lipid A of W674 and A26 were converted to
methyl esters by the method of Poxton and Cartmill (1982) and
analysed by gas chromatography.
The composition of fatty acids of lipid A fraction of the two
strains are given in Table 6.10. The amounts indicated are in
molar proportions in relation to 3-hydroxytetradecanoate (3 OH
C14:0) calculated from area percentages. The molar proportions of
fatty acids varied in that W674 contained a higher proportion of
the tetradecanoate (C14:0) and less of the hexadecanoate (C16:0) as
shown in Table 6.10.
The chromatogram of lipid A of W674 is shown in fig. 6.18.
Strain A26 also demonstrated a similar pattern and therefore not
indicated here.
6.7. Fusion two
A second fusion was performed with mouse nos. 6 and 7 (fig.
6.1 (b)) after iv boost 3 days prior to fusion. A total of 153
hybrids were screened for antibody production and only 11 were
Fig. 6.16. Gas chromatograms of alditol acetate
derivatives of hydrolysed polysaccharide
fraction of LPS of W674 (a) and A26 (b) on a
capillary column of SIL 84 for the detection
of sugars. Temperature programme was 220°C for
2 min, l°C/min to 240°C for 2 min
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Fig. 6.16.
METHOD 4- SILB4 5,6 OH
METHOD 4 SIL84 5, G OH
Fig. 6.17. Gas chromatograms of alditol acetate
derivatives of hydrolysed polysaccharide
fraction of LPS of A26 (a) and W674 (b) on a
capillary column of BP 20 for the detection of
sugars. Temperature programme was 220°C for 4
min, 2°C/min to 240°C for 4 min, 2°C/min to
250°C for 10 min.
30
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Table 6.10. Comparison of the lipid A fraction of A26
and W674 LPS






(30H C14:0) 1.0 1.0
Me. Cis-9-
hexadecanoate
(C16:1 ) 0.08 0.1
Me. hexadecanoate
(C16:0) 0.25 0.1
Fig. 6.18. Gas chromatograra of methyl ester
derivatives of methanolysed lipid A fraction
of LPS of W674 on a capillary column BP 1 for
the detection of fatty acids. Temperature
programme was 150°C for 4 min, 4°C/min to
250°C for 2 min.
1. Me. tetradecanoate (C14:0)
2. Me. 3-hydroxytetradecanoate (30H C14:0)
9
3. Me. Cis-9-hexadecanoate (C16:l )
4. Me. hexadecanoate (C16:0)





found to be positive in whole-cell ELISA. Of these, three cell
lines continued to produce antibodies after the second cloning by
limited dilution method. An IgM antibody (2/4-7-9) was found to be
reactive against LPS (proteinase K digests) in Western blotting.
One other mAb (2/8-9-26) was positive in dot blots against the
crude capsular extract and belonged to IgM class. The remaining
mAb which was an IgG^ did not react with proteins or against LPS in
Western blotting. No further studies could be carried out on these
mAb because of the time limit.
DISCUSSION
Monoclonal antibodies were raised by immunizing mice with P.
mulCocida whole cells. Only three out of eight mAb could be
characterized. These were specific for capsule, LPS and an outer
membrane protein.
The dominant precipitation arc observed in crossed
Immunoelectrophoresis and the low IHA titre at which the antibodies
agglutinated capsule-coated red cells suggested that the antibodies
might be directed against the hyaluronic acid capsule. This notion
is supported by the fact that the capsule of mucoid type A is
largely composed of hyaluronic acid (Carter 1958) which is neither
immunogenic nor specific (Carter and Annau 1953). Although this
antibody agglutinated capsule-coated red cells with the homologous
strain only, a slight agglutination was observed with serotypes A
and D type cultures which suggested that the antigen was present in
both of these strains but was lacking in all the other strains of
type A. The presence of hyaluronic acid in most type A strains and
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to a lesser extent in type D strains was reported by Carter
(1972b). The haemagglutination pattern observed in this study
(table 6.2) with different strains, and polyclonal rabbit serum
indicates the specificity of this test. Not all type A strains,
however, were agglutinated with rabbit antiserum. The involvement
of LPS in this assay has been indicated by Bain and Knox (1961) and
Carter and Rappay (1963) bringing into question the serotype
specificity of this assay.
The hybridoma cells which produced the mAb (1/2-16-8) that
reacted with a component of the crude capsular antigen died during
storage, which made further studies not possible. It was intended
to examine the chemical nature of the antigen against which this
antibody reacted by crossed-immunoelectrophoresis by heating the
capsular antigen to 100°C and treating with periodate and proteases
prior to electrophoresis.
The "capsular" antibody had no involvement in the complement
mediated killing of bacteria in vitro, had no ability to protect
mice passively, but could enhance phagocytosis by mouse peritoneal
macrophages. Treatment of bacteria with hyaluronidase to
decapsulate them did not increase the percentage phagocytosed. In
mice, this anti-capsule antibody plays a very small role in their
immune mechanisms. This IgM antibody which reacted mainly with the
homologous strain in IHA, is more likely to be against a
strain-specific surface antigen than the capsular hyaluronic acid.
The hybridoma cells which were producing the anti-77 kDa protein
antibody ceased secreting antibody thus limiting more detailed
studies of this antibody. From the results it was apparent that
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the IgG antibody was not bactericidal and not protective in mice.
This is in contrast to the findings of Lu et al (1987b) where
hyperimmune rabbit serum containing a high titre of IgG antibody
directed mainly against the 37.5 kDa protein was protective in
rabbits. However, the mechanism by which the protection resulted
by these antibodies was not defined by those authors.
Five of the eight mAb in this present study could not be
characterized, although they all reacted in whole cell ELISA. None
of them reacted in IHA or in LPS Western blots indicating that they
were not against the capsule or LPS. The failure of recognition of
proteins by Western blotting might be an indication of the loss or
denaturation of epitopes during the complex process involved in
separation on PAGE and transfer to NC. These antibodies may react
with undenatured proteins on intact bacteria. The inability to
demonstrate protein specificity by th£ mAb against Ehrlichia
risticii has also been reported by Shankarappa and Dutta (1989b) .
An encouraging finding in this study is the ability of the IgGj
anti-LPS mAb to protect mice, which is clearly associated with the
complement-dependent antibody-mediated lysis of bacteria. This
same antibody seems to enhance phagocytosis of P. multocida by the
peritoneal macrophages. Similarly, two anti-capsule mAbs to P.
haemolytica Amediating both these mechanisms have been reported
by Penaredondo et al (1988).
The epitope recognised by the anti-LPS mAb does not appear to be
present in 42% of P. multocida and the other Gram-negative
organisms tested. Correlation (P < 0.001) of whole-cell ELISA
titres to the bactericidal capacity of this antibody against
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different strains, highlights the use of either of these assays to
interpret the immune status of mice. From the previous study
(Chapter 5), involvement of a cell surface antigen in this
mechanism of immunity was suggested, since the bactericidal
capacity of mouse polyclonal serum correlated well (P < 0.001) with
whole-cell ELISA titres. It is now very clear that the LPS is this
cell surface antigen and that the anti-LPS antibodies play a major
role in the immune mechanisms of mice.
The structural specificity of this monoclonal was found to be
directed against the lipid A moiety of the LPS. As lipid A is the
most conserved structural element of LPS, a degree of
cross - reactivity of the lipid A antibodies can be expected to exist
between different species of bacteria (Johns et al 1977). However,
more recent work has shown that mAbs to lipid A are restrictive in
their specificity rather than cross-reactive (Pollack et al 1989),
which is in agreement with the present findings.
The structural analysis of LPS of two strains showed similar
chemical compositions. However, the sugar compositions of the
polysaccharide fraction of the two strains were found to be
different, while lipid A moities were constituted of identical
fatty acids but in varying molar proportions. These findings are
in agreement with the other reports that the lipid A is the most
conservative part of the LPS molecule (Brade et al 1988; Pollack et
al 1989).
However, it must be noted that the specificity of this anti-LPS
mAb as determined by inhibition of ELISA appeared to be directed
towards the lipid A. In this case, it could be anticipated that
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the differences may occur in the lipid A moiety of these two
strains. Whether the different molar proportions of the 2 fatty
acids (C14:0 and C16:0) detected in strain W674 were responsible
for this specificity of the mAb is questionable. As pointed out by
Brade et al (1988), in any serological test the ability of lipid A
to generate a completely different physicochemical surrounding may
have influenced the results obtained in the ELISA inhibition in
this study. They also added that the lipid A could interact with
plastic surfaces in the ELISA test which may change the
supramolecular structure (conformation) of lipid A.
Although the studies carried out on LPS in this thesis were
limited and could not arrive at any conclusion, they opened up
avenues for future research, which will lead to better
understanding of the immunogenicity and antigenicity of the LPS of
P. multocida.
It will be interesting to study the structure of the LPS of a
greater number of selected strains of P. multocida based on the
ELISA results obtained in this study. Also, more advanced methods
such as nuclear magnetic reasonance (NMR) spectrometry and GC -
mass spectrometry techniques would have been helpful to confirm the




The studies described in this thesis were aimed at identifying
the protective antigen(s) and the effector mechanism(s) of immunity
to P. multocida in mice.
The antigens responsible for homologous and heterologous
protection are not yet defined. Attempts have been made to
identify the subcellular constituents of P. multocida in the hope
that better vaccines than those currently available could be
developed. Capsular polysaccharides of serotypes B and E are
protective against haemorrhagic septicaemia (Penn and Nagy 1974;
Nagy and Penn 1976). However, capsular substances may not be
important in protection against fowl cholera because immunity can
be induced by non-capsulate as well as capsulate avian strains of
P. multocida (Heddleston et al 1964). Tissue vaccines or vaccines
containing in vivo grown cells induced better immunity than did
ordinary bacterins, and were also cross-protective (Heddleston and
Rebers 1972; Rebers and Heddleston 1977).
Therefore, investigations aimed at simulating the antigen
expression that would probably occur in cells grown in vivo and
their protective ability in mice were carried out. Iron scarcity
is one of the factors bacteria have to overcome in the host. In
order to assimilate bound iron from host-binding proteins most
bacteria produce siderophores (Barclay 1985) and/or high-molecular
mass outer membrane proteins (Overbeeke and Lugtenberg 1980) .
Certain other bacteria e.g. Bordetella pertussis and Neisseria
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meningitidis seem to obtain iron directly from the host
iron-binding proteins via cell surface mechanisms (Redhead et al
1987; Schryvers and Morris 1988). These authors have suggested
that the iron regulated proteins or receptors on bacteria for
lactoferrin or transferrin may be possible vaccine candidates.
Investigations into the expression of these proteins by P.
multocida under iron limitation in vitro and in vivo were carried
out. P. multocida type A of bovine origin recovered from the
pleural fluid of experimentally infected lambs expressed two unique
outer membrane proteins of molecular masses of 84 and 87 kDa.
These proteins were also expressed in cells grown in vitro under
iron depleted conditions in nutrient broth containing
2,2'-dipyridyl, but not in bacteria grown in nutrient broth only.
Ikeda and Hirsh (1988) reported the expression of a protein of 84
kDa by all the somatic types of P. multocida when they were grown
in BHIB containing 2,2dipyridyl. This was in agreement with the
findings of the present study. However, in addition to this 84 kDa
protein, two other proteins of 80 and 96 kDa were observed by
Snipes et al (1988) when turkey P. multocida was grown in turkey
plasma at 41°C and in BHIB with 2,2'-dipyridyl. These two proteins
were not observed in this present study.
Mice immunized with heat killed organisms which had been grown
in nutrient broth, nutrient broth containing 2,2'-dipyridyl, horse
serum and in vivo demonstrated good homologous protection. There
was a suggestion that the vaccine which contained cells grown in
nutrient broth with 2,2'-dipyridyl induced a slightly higher
protection against challenge than the others. However, this
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protection was not significantly better on statistical analysis. It
is apparent that in mice all vaccines give good protection and
therefore it was difficult to show better protection. A greater
antibody response was also observed in sera of mice immunized with
bacteria expressing iron regulated proteins compared to the other
growth condition as determined by ELISA. This higher antibody
response can not be accounted for by the presence of iron regulated
proteins as no antibody response against the 84 and 87 kDa proteins
could be demonstrated in Western blots. Instead, growth of P.
multocida under iron-restricted conditions in vitro may have
produced a different antigenic profile to which mice responded.
This is supported by the appearance of two additional low molecular
mass proteins recognized by the sera from this same group of mice.
In the same experiment, when the virulence (LD^q) of bacteria
grown under different cultural conditions was tested, it was found
that nutrient broth grown and in vivo cells were the most virulent
in mice. If outer membrane proteins are responsible for the
virulence, then it could be expected that bacteria expressing
iron-regulated proteins would be more virulent. This is the case
with certain Yersinia species, where presence of iron-regulated
proteins (IRP) correlated with the degree of virulence of the
species (Carniel et al 1987). In the present study the presence of
IRP did not correlate with the virulence of bacteria. Since the
capsule of P. multocida is also not related to virulence (Curtis et
al 1980) it may be the LPS of the organism that is associated with
virulence as indicated by Poxton and Arbuthnott (1990). More work
has to be done on the expression of IRP by P. multocida and their
role in immunity with special reference to cattle.
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Studies which were carried out with a view to identifying the
effector mechanism(s) of immunity to P. multocida indicated that
the complement-mediated bactericidal activity of immune mouse serum
is an important mechanism. In this study the protection in mice
was clearly associated with the bactericidal antibodies. The
correlation of bactericidal capacity with whole-cell ELISA
suggested that cell surface antigens were involved in stimulating
bactericidal antibodies. In most other Gram-negative bacteria LPS
has been identified as this target antigen (Taylor 1983; Sutherland
1988) .
Although immune mouse serum showed the ability to
opsonophagocytose P. multocida, it was to a very low percentage
in comparison to what was observed for P. haemolytica (Sutherland,
thesis in preparation 1989). Therefore, it is not clear whether
the phagocytosis enhanced by immune mouse serum is significant in
protection.
The anti-LPS mAb gave substantial evidence that LPS has a
crucial role in protection of mice against P. multocida infection.
The association observed between the whole-cell ELISA titres,
bactericidal capacity and Western blotting of LPS of different
isolates of P. multocida suggested that the complement-mediated
antibody-dependent killing is an important mechanism of immunity to
P. multocida in mice. This also indicated that LPS is the target
antigen in this mechanism of immunity.
LPS has been implicated as the important immunogen when
complexed with protein in chickens, mice and rabbits (Heddleston et
al 1972; Rebers et al 1980; Rebers and Heddleston 1974; Ganfield
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et al 1976; Syuto and Matsumoto 1982; Tsuji and Matsumoto 1988 (a)
and (b)). Purified LPS was toxic and was found to be immunogenic
only in chickens and not in mice or rabbits (Rebers et al 1980) .
The requirement of LPS in ribosomal vaccines for the induction of
immunity was demonstrated by Phillips and Rimler (1984). All these
studies indicate the importance of LPS in inducing immunity against
P. multocida. Although very little work has been carried out in
cattle on this aspect, a report of detection of elevated levels of
antibody to a crude LPS preparation and certain proteins in sera of
cattle vaccinated against haemorrhagic septicaemia also suggested
the role of LPS in immunity in P. multocida (Johnson et al 1989).
Whether the presence of these antibodies correlate with protection
has not been studied by these authors.
The passive protection experiments carried out in mice also
indicated that only anti-LPS antibodies could protect mice while
the anti-capsule and the anti-protein (77 kDa) were not protective
against the challenge. Although the anti-LPS mAb enhanced
phagocytosis by peritoneal macrophages, it is evident that the
mechanism by which it brings about protection is
complement-mediated bacteriolysis. Its structural specificity
towards lipid A, as suggested by ELISA inhibition, supports the
assumption that the fixing of complement close to the cell membrane
causes lysis of bacteria. This hypothesis is furher-supported by
the findings of an anti-LPS mAb raised against P. haemolytica
reactive against the more distal polysaccharide moiety being not
bactericidal (Wilson et al 1989, personal communication).
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The structural studies of LPS and their lipid A and
polysaccharide fractions from two strains of P. multocida was
aimed at expanding the knowledge on the structure of LPS in
relation to the specificity of the mAb. From the techniques
employed, although differences between the two strains were
detected especially in the polysaccharide fraction, no firm
conclusions could be made. The lipid A moieties of the two strains
contained the same fatty acids but in different molar proportions.
Hydroxy fatty acids, which are typical of LPS of other bacteria,
were also present.
Future research therefore should concentrate on a more detailed
study of the structure of LPS from more strains: which react with
the anti-LPS mAb and those which did not react, using more
powerful techniques. The protective ability of either crude or
purified LPS must be studied in cattle and the effector mechanisms
of immunity also need more extensive investigations. Since LPS is
the criterion for somatic serotyping of P. multocida more
attention has to be placed on this complex molecule prior to
planning any future animal experiments. As it is well known that
the capsular type A strains consist of several different somatic
(0) types, a wide range of these (0) types must also be
investigated in detail. This will be of value in the rational
development of cattle vaccines.
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Publications arising from thesis
1. Bactericidal activity in the sera of mice vaccinated against
P. multocida
2. Production and characterization of monoclonal antibodies
against P. multocida type A.
3. Immunological properties of a monoclonal antibody specific
for lipopolysaccharide of P. multocida type A.
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APPENDIX 1
1.1. Chegker-board titration of NB grown P. multocida
(10 cfu/ml) as antigen and mouse immune serum
from chamber implanted mice as the standard
positive serum




IO"1 io"2 io"3 io"4 io"5 lO"6
-1
10 0.96 0.92 0.87 0.72 0.81 0.67
10"2 0.79 0.61 0.49 0.49 0.51 0.39
IO"3 0.88 0.61 0.24 0.30 0. 39 0.19
-
0.4310 0.52 0.26 0.24 0.20 0.11
io"5 0.31 0.27 0.17 0.19 0.13 0.07
kO1
o»—1 0.19 0.14 0.09 0.08 0.04 0.00
Antigen dilution 10 ^ (10^ cfu/ml) and
-2
Antibody dilution 10 were selected
1.2. Screening of hybrids for antibody production by
indirect ELISA.
Optical densities of twenty positive hybrids
Cell line OD 492nm Cell line OD 492 nm
1/1 1.157 1/11 0.531
1/2 0.586 1/12 0.571
1/3 0.622 1/13 0.807
1/4 1.847 1/14 0.560
1/5 0.511 1/15 0.577
1/6 1.206 1/16 1.084
1/7 1.413 1/17 0.536
1/8 0.547 1/18 0.518
1/9 0.802 1/19 0.523
1/10 0.917 1/20 0.594
Standard positive polyclonal serum when doubly-diluted









































































































































































































2.1. List of bacterial strains tested against the anti-
LPS mAb by ELISA
X12 X1113 A513
W669 A341 A514
A3 3 X223 Type A (10322)
X120 A757 Type B (10323)
A26 QUO Type D (10325)
X9 W735A Type E (10326)
W674 A34 K. oxytoca (A405/2)
W829 A515 S. montevideo(A459/1)
X110 W666 S. arizonae (A459/2)
X200 X1016 s. derby (A459/27)
A87 A872 Ser.liquefaciens (A405/1)
X1122 812 E. coli (A405/3)
X1053 396 Y. pseudotuberculosis (A1218)
A55 A586 P. haemolytica A1
A394 W598 P. haemolytica A2
X188 W861 P. haemolytica T3
A3 6 X1057 P. haemolytica T4
A440 X142 P. haemolytica A5
A419 A82 P. haemolytica A6
A1174 A79 P. haemolytica A7
A848 W828 P. haemolytica A8
X109 X1056 P. haemolytica A9
P. haemolytica T10
P. haemolytica All
P. haemolytica A12
P. haemolytica A13
P. haemolytica A14
P. haemolytica T15
P. haemolytica A16
L. monocytogenes (4B)
